1 | **Comment**- IMP inhalation solution identical to ventavis inhalation solution, but IMP is in a different volume presentation. Please see covering letter. | 1件: Iloprost Iloprost | 1件: D02721
D02721
| 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 |
2 | 1 mg QD to 15 mg QD PF-06649751 | 1件: Tavapadon Tavapadon | 1件: D11431
D11431
| 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 |
3 | 1 mg QD to 7 mg QD PF-06649751 (if de-escalated in parent study) | 1件: Tavapadon Tavapadon | 1件: D11431
D11431
| 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 |
4 | 10% Metronidazole Ointment (Synonym: METRONIDAZOLE TOPICAL CREAM) | 1件: Metronidazole Metronidazole (Synonym: Metronidazole Topical Gel) | 1件: D00409
D00409
(Name: METRONIDAZOLE TOPICAL CREAM) | - | - | 1件: 96 96 |
5 | 15 mg QD de-escalated to 7 mg QD PF-06649751 in parent study remain at 7 mg QD | 1件: Tavapadon Tavapadon | 1件: D11431
D11431
| 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 |
6 | 15N2-tofacitinib | 1件: Tofacitinib Tofacitinib | 1件: D09970
D09970
(Name: Tofacitinib) | 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 97 97 |
7 | 3 mg QD to 15 mg QD PF-06649751 | 1件: Tavapadon Tavapadon | 1件: D11431
D11431
| 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 |
8 | 3 mg QD to 7 mg QD PF-06649751 (de-escalated in parent study) | 1件: Tavapadon Tavapadon | 1件: D11431
D11431
| 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 |
9 | 7 mg QD to 15 mg QD PF-06649751 | 1件: Tavapadon Tavapadon | 1件: D11431
D11431
| 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 |
10 | 7 mg QD to 7 mg QD PF-06649751 (de-escalated in parent study) | 1件: Tavapadon Tavapadon | 1件: D11431
D11431
| 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 |
11 | Abatacept, rituximab or tocilizumab | 3件: Abatacept Abatacept, Rituximab, Tocilizumab | 3件: D02596
D02596
(Name: Tocilizumab),
D02994
,
D03203
| 4件: CD80 CD80, CD86, IL6R, MS4A1 💬 | 25件: Allograft rejection Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Rheumatoid arthritis, Systemic lupus erythematosus, Th17 cell differentiation, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis, Viral protein interaction with cytokine and cytokine receptor, Virion - Adenovirus 💬 | 1件: 46 46 |
12 | ABP 710 - Biosimilar to infliximab | 1件: Infliximab Infliximab | 1件: D02598
D02598
| 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 |
13 | ABP 798 - Biosimilar to rituximab | 1件: Rituximab Rituximab | 1件: D02994
D02994
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 46 46 |
14 | ABP 798 Biosimilar to Rituximab | 1件: Rituximab Rituximab | 1件: D02994
D02994
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 46 46 |
15 | ABP 959 - biosimilar to eculizumab | 1件: Eculizumab Eculizumab | 1件: D03940
D03940
| 1件: C5 C5 💬 | 11件: Alcoholic liver disease Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬 | 1件: 62 62 |
16 | ABP 959 - proposed biosimilar to eculizumab | 1件: Eculizumab Eculizumab | 1件: D03940
D03940
| 1件: C5 C5 💬 | 11件: Alcoholic liver disease Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬 | 1件: 62 62 |
17 | AC-203 1% Topical Ointment | - | - | - | - | 1件: 162 162 |
18 | Active topical NS2 1% dermatologic cream | - | - | - | - | 1件: 160 160 |
19 | Adalimuab, Etanercept, Tocilizumab, or Abatacept | 3件: Abatacept Abatacept, Etanercept, Tocilizumab | 3件: D00742
D00742
,
D02596
(Name: Tocilizumab),
D03203
| 5件: CD80 CD80, CD86, IL6R, LTA, TNF 💬 | 80件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, Autoimmune thyroid disease, C-type lectin receptor signaling pathway, Cell adhesion molecules, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Transcriptional misregulation in cancer, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral myocarditis, Viral protein interaction with cytokine and cytokine receptor, Virion - Adenovirus, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 |
20 | Adalimumab (up to 9 months exposure) | 1件: Adalimumab Adalimumab | 1件: D02597
D02597
| 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 |
21 | ADENO-ASSOCIATED VIRUS SEROTYPE 5 ENCODING A MICRORNA TARGETED TO HUMAN HUNTINGTIN GENE | - | - | - | - | 1件: 8 8 |
22 | ADX-102 1% Topical Dermal Cream (reproxalap) | 1件: Reproxalap Reproxalap | 1件: D11309
D11309
| - | - | 1件: 160 160 |
23 | Alpha-tocopherol | 2件: Tocopherol Tocopherol, Vitamin E (Synonym: alpha-tocopherol) | 2件: D02331
D02331
,
D02332
(Name: Tocopherol) | - | - | 2件: 49 49, 206 |
24 | Alpha-tocotrienol quinone | 1件: Tocotrienol Tocotrienol | - | - | - | 2件: 21 21, 156 |
25 | Alpha-tocotrienolquinone | - | - | - | - | 1件: 18 18 |
26 | Also referred to as 'MEDI2070' | - | - | - | - | 2件: 96 96, 97 |
27 | Also referred to as MED2070 | - | - | - | - | 1件: 96 96 |
28 | Also referred to as MEDI2070 | - | - | - | - | 2件: 96 96, 97 |
29 | Alvelestat tosylate | 1件: Alvelestat Alvelestat | - | - | - | 1件: 231 231 |
30 | Amoxicillin, metronidazole and doxycycline (Synonym: METRONIDAZOLE TOPICAL CREAM) | 3件: Amoxicillin Amoxicillin, Doxycycline, Metronidazole (Synonym: Metronidazole Topical Gel) | 5件: D00229
D00229
,
D00307
,
D00409
(Name: METRONIDAZOLE TOPICAL CREAM),
D07452
,
D07876
| - | - | 1件: 97 97 |
31 | AndroGel 1 % Topical Gel | - | - | - | - | 1件: 13 13 |
32 | Anesthetic Topical Adhesive Synera | - | - | - | - | 1件: 13 13 |
33 | Antiepileptic drug (1 to 3 only) | - | - | - | - | 1件: 158 158 |
34 | Apitox - pure honeybee toxin | - | - | - | - | 1件: 13 13 |
35 | Ascorbic Acid (Vitamin C) and Alpha-tocopherol (Vitamin E) | 3件: Ascorbic acid Ascorbic acid (Synonym: Hot Lemon Ultra Strength Total Flu Night), Tocopherol, Vitamin E (Synonym: alpha-tocopherol) | 3件: D00018
D00018
,
D02331
,
D02332
(Name: Tocopherol) | - | - | 1件: 206 206 |
36 | Atomoxetine (Synonym: Tomoxetine) | 1件: Atomoxetine Atomoxetine (Synonym: Tomoxetine) | 1件: D07473
D07473
(Name: Tomoxetine) | 1件: SLC6A2 SLC6A2 💬 | 1件: Synaptic vesicle cycle Synaptic vesicle cycle 💬 | 4件: 6 6, 8, 13, 17 |
37 | Autologous mature tolerogenic monocyte-derived Dendritic Cells loaded with the B29 peptide of HSP70 | - | - | - | - | 1件: 46 46 |
38 | Autologous VitD3 tolerogenic monocyte-derived dendritic cells loaded with a pool of myelin peptides (tolDC-VitD3) | 1件: Myelin basic protein Myelin basic protein | - | - | - | 1件: 13 13 |
39 | Avonex and Topamax | 1件: Interferon beta-1a Interferon beta-1a | 1件: D04554
D04554
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
40 | Azithromycin + Metronidazole (Synonym: METRONIDAZOLE TOPICAL CREAM) | 2件: Azithromycin Azithromycin, Metronidazole (Synonym: Metronidazole Topical Gel) | 3件: D00409
D00409
(Name: METRONIDAZOLE TOPICAL CREAM),
D06390
,
D07486
| - | - | 1件: 96 96 |
41 | BDMARD withdrawal (etanercept, adalimumab, infliximab, certolizumab, golimumab, tozilizumab, abatacept) | 5件: Abatacept Abatacept, Adalimumab, Etanercept, Golimumab, Infliximab | 5件: D00742
D00742
,
D02597
,
D02598
,
D03203
,
D04358
| 4件: CD80 CD80, CD86, LTA, TNF 💬 | 74件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, Autoimmune thyroid disease, C-type lectin receptor signaling pathway, Cell adhesion molecules, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Transcriptional misregulation in cancer, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral myocarditis, Viral protein interaction with cytokine and cytokine receptor, Virion - Adenovirus, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 |
42 | Bezafibrate (400mg) in addition to standard 15-20 mg/kg/jour UDCA therapy | 2件: Bezafibrate Bezafibrate, Ursodeoxycholic acid (Synonym: BAMBOO SALT Eunganggo Jook Yeom Toothpaste) | 2件: D00734
D00734
,
D01366
| 2件: NR1H4 NR1H4, PPARA 💬 | 11件: Adipocytokine signaling pathway Adipocytokine signaling pathway, Alcoholic liver disease, Bile secretion, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬 | 1件: 94 94 |
43 | BIIB067 (Tofersen) | 1件: Tofersen Tofersen | 1件: D11811
D11811
(Name: Tofersen) | 1件: SOD1 SOD1 💬 | 8件: Amyotrophic lateral sclerosis Amyotrophic lateral sclerosis, Chemical carcinogenesis - reactive oxygen species, Huntington disease, Longevity regulating pathway - multiple species, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Peroxisome, Prion disease 💬 | 1件: 2 2 |
44 | Biological: Benralizumab, Biological: Placebo to Mepolizumab | 2件: Benralizumab Benralizumab, Mepolizumab | 2件: D04923
D04923
,
D09874
| 2件: IL5 IL5, IL5RA 💬 | 13件: Allograft rejection Allograft rejection, Asthma, Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Inflammatory bowel disease, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Pathways in cancer, T cell receptor signaling pathway, Th1 and Th2 cell differentiation 💬 | 1件: 44 44 |
45 | Biological: Mepolizumab, Biological: Placebo to Benralizumab | 2件: Benralizumab Benralizumab, Mepolizumab | 2件: D04923
D04923
,
D09874
| 2件: IL5 IL5, IL5RA 💬 | 13件: Allograft rejection Allograft rejection, Asthma, Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Inflammatory bowel disease, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Pathways in cancer, T cell receptor signaling pathway, Th1 and Th2 cell differentiation 💬 | 1件: 44 44 |
46 | Biosimilar product to adalimumab | 1件: Adalimumab Adalimumab | 1件: D02597
D02597
| 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 |
47 | Bony Toxicity | - | - | - | - | 1件: 34 34 |
48 | Bortezomib D-mannitol (Synonym: Tobrex (TN)) | 2件: Bortezomib Bortezomib, Mannitol | 2件: D00062
D00062
(Name: Tobrex (TN)),
D03150
| 1件: PSMB5 PSMB5 💬 | 8件: Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Prion disease, Proteasome, Spinocerebellar ataxia 💬 | 1件: 28 28 |
49 | Botulinic toxin | - | - | - | - | 1件: 36 36 |
50 | Botulinum A toxin | - | - | - | - | 1件: 118 118 |
51 | Botulinum Toxin | - | - | - | - | 3件: 6 6, 13, 149 |
52 | Botulinum toxin A | 1件: Botulinum toxin type A Botulinum toxin type A | 1件: D00783
D00783
(Name: Botulinum toxin type A) | 1件: SNAP25 SNAP25 💬 | 2件: Insulin secretion Insulin secretion, Synaptic vesicle cycle 💬 | 4件: 13 13, 51, 149, 226 |
53 | BOTULINUM TOXIN A - HAEMAGGLUTININ COMPLEX | 1件: Botulinum toxin type A Botulinum toxin type A | 1件: D00783
D00783
(Name: Botulinum toxin type A) | 1件: SNAP25 SNAP25 💬 | 2件: Insulin secretion Insulin secretion, Synaptic vesicle cycle 💬 | 1件: 13 13 |
54 | BOTULINUM TOXIN TYPE A | 1件: Botulinum toxin type A Botulinum toxin type A | 1件: D00783
D00783
(Name: Botulinum toxin type A) | 1件: SNAP25 SNAP25 💬 | 2件: Insulin secretion Insulin secretion, Synaptic vesicle cycle 💬 | 10件: 2 2, 5, 6, 7, 13, 15, 17, 70, 113, 149 |
55 | Botulinum toxin type A (Nabota®) injection into the gastrocnemius muscle | 1件: Botulinum toxin type A Botulinum toxin type A | 1件: D00783
D00783
(Name: Botulinum toxin type A) | 1件: SNAP25 SNAP25 💬 | 2件: Insulin secretion Insulin secretion, Synaptic vesicle cycle 💬 | 1件: 70 70 |
56 | Botulinum Toxin Type A 200U | 1件: Botulinum toxin type A Botulinum toxin type A | 1件: D00783
D00783
(Name: Botulinum toxin type A) | 1件: SNAP25 SNAP25 💬 | 2件: Insulin secretion Insulin secretion, Synaptic vesicle cycle 💬 | 1件: 13 13 |
57 | Botulinum Toxin Type A 300U | 1件: Botulinum toxin type A Botulinum toxin type A | 1件: D00783
D00783
(Name: Botulinum toxin type A) | 1件: SNAP25 SNAP25 💬 | 2件: Insulin secretion Insulin secretion, Synaptic vesicle cycle 💬 | 1件: 13 13 |
58 | Botulinum toxin type B | 1件: Botulinum toxin type B Botulinum toxin type B | 1件: D02735
D02735
(Name: Botulinum toxin type B (JAN)) | 1件: SNAP25 SNAP25 💬 | 2件: Insulin secretion Insulin secretion, Synaptic vesicle cycle 💬 | 3件: 2 2, 6, 51 |
59 | Botulinum toxin type B (2500 units / vial) | 1件: Botulinum toxin type B Botulinum toxin type B | 1件: D02735
D02735
(Name: Botulinum toxin type B (JAN)) | 1件: SNAP25 SNAP25 💬 | 2件: Insulin secretion Insulin secretion, Synaptic vesicle cycle 💬 | 1件: 51 51 |
60 | Botulinum toxin type B (Myobloc) | 1件: Botulinum toxin type B Botulinum toxin type B | 1件: D02735
D02735
(Name: Botulinum toxin type B (JAN)) | 1件: SNAP25 SNAP25 💬 | 2件: Insulin secretion Insulin secretion, Synaptic vesicle cycle 💬 | 2件: 2 2, 6 |
61 | Botulinum toxin(Botox) | 1件: Botulinum toxin type A Botulinum toxin type A | 1件: D00783
D00783
(Name: Botulinum toxin type A) | 1件: SNAP25 SNAP25 💬 | 2件: Insulin secretion Insulin secretion, Synaptic vesicle cycle 💬 | 1件: 51 51 |
62 | Botulinum Toxin: Xeomin | 1件: Botulinum toxin type A Botulinum toxin type A | 1件: D00783
D00783
(Name: Botulinum toxin type A) | 1件: SNAP25 SNAP25 💬 | 2件: Insulin secretion Insulin secretion, Synaptic vesicle cycle 💬 | 1件: 6 6 |
63 | Botulism Toxin Treatment | - | - | - | - | 1件: 161 161 |
64 | C-82 Topical Gel, 1% | - | - | - | - | 1件: 51 51 |
65 | C-type natriuretic peptide conjugated to a multi-arm polyethylene glycol carrier molecule through a cleavable linker | 1件: Polyethylene glycol Polyethylene glycol (Synonym: Topcare ClearLax) | 1件: D03370
D03370
| - | - | 1件: 276 276 |
66 | C-TYPE NATRIURETIC PEPTIDE CONJUGATED TO MULTI-ARM POLYETHYLENE GLYCOL CARRIER THROUGH A CLEAVABLE LINKER | 1件: Polyethylene glycol Polyethylene glycol (Synonym: Topcare ClearLax) | 1件: D03370
D03370
| - | - | 1件: 276 276 |
67 | Ceftazidime and tobramycin | 2件: Ceftazidime Ceftazidime, Tobramycin | 3件: D00063
D00063
(Name: Tobramycin),
D00921
,
D07654
| - | - | 1件: 299 299 |
68 | Chong Kun Dang Tofacitinib Tablet | 1件: Tofacitinib Tofacitinib | 1件: D09970
D09970
(Name: Tofacitinib) | 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 46 46 |
69 | Cistanche Total Glycosides | - | - | - | - | 1件: 2 2 |
70 | Clobetasol 0.05% Topical Ointment | 1件: Clobetasol Clobetasol | 1件: D07715
D07715
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 162 162 |
71 | CLOSTRIDIUM BOTULINUM TOXIN TYPE A | 2件: Botulinum toxin type A Botulinum toxin type A, Clostridium botulinum | 1件: D00783
D00783
(Name: Botulinum toxin type A) | 1件: SNAP25 SNAP25 💬 | 2件: Insulin secretion Insulin secretion, Synaptic vesicle cycle 💬 | 1件: 13 13 |
72 | Cohort 1: hATG, CsA, EPAG Day 14 to Month 6 | 1件: Antilymphocyte immunoglobulin (horse) Antilymphocyte immunoglobulin (horse) | - | - | - | 1件: 60 60 |
73 | Cohort 2: hATG, CsA, EPAG Day 14 to Month 3 | 1件: Antilymphocyte immunoglobulin (horse) Antilymphocyte immunoglobulin (horse) | - | - | - | 1件: 60 60 |
74 | Cohort 2: Nilotinib Oral Capsules (dose to be determined from Cohort 1) | 1件: Nilotinib Nilotinib | 1件: D08953
D08953
| 4件: ABL1 ABL1, KIT, PDGFRA, PDGFRB 💬 | 33件: Acute myeloid leukemia Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Viral myocarditis 💬 | 1件: 6 6 |
75 | Cohort 3: hATG, CsA (dose reduced), EPAG day 1 to month 6 | 1件: Antilymphocyte immunoglobulin (horse) Antilymphocyte immunoglobulin (horse) | - | - | - | 1件: 60 60 |
76 | Combination Product: Beclomethasone dipropionate in addition to MC-EVOO | 1件: Beclomethasone dipropionate Beclomethasone dipropionate | 1件: D00689
D00689
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 97 97 |
77 | Combination Product: Beclomethasone dipropionate in addition to refined oil | 1件: Beclomethasone dipropionate Beclomethasone dipropionate | 1件: D00689
D00689
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 97 97 |
78 | Corticoids+ tocilizumab 8mg/Kg/4 weeks | 1件: Tocilizumab Tocilizumab | 1件: D02596
D02596
(Name: Tocilizumab) | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 41 41 |
79 | Cotoretigene Toliparvovec | 1件: Cotoretigene toliparvovec Cotoretigene toliparvovec | - | - | - | 1件: 90 90 |
80 | CP-690,550 (tofacitinib) | 1件: Tofacitinib Tofacitinib | 1件: D09970
D09970
(Name: Tofacitinib) | 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 2件: 46 46, 107 |
81 | CT-P47 AI (tocilizumab) | 1件: Tocilizumab Tocilizumab | 1件: D02596
D02596
(Name: Tocilizumab) | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 46 46 |
82 | CT-P47 PFS (tocilizumab) | 1件: Tocilizumab Tocilizumab | 1件: D02596
D02596
(Name: Tocilizumab) | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 46 46 |
83 | Cystic Fibrosis Ready to Use Supplemental Food | - | - | - | - | 1件: 299 299 |
84 | D-a-tocopheryl PEG 1000 succinate | - | - | - | - | 1件: 299 299 |
85 | Decrease Tocilizumab, Abatacept | 2件: Abatacept Abatacept, Tocilizumab | 2件: D02596
D02596
(Name: Tocilizumab),
D03203
| 3件: CD80 CD80, CD86, IL6R 💬 | 25件: Allograft rejection Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Rheumatoid arthritis, Systemic lupus erythematosus, Th17 cell differentiation, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis, Viral protein interaction with cytokine and cytokine receptor, Virion - Adenovirus 💬 | 1件: 46 46 |
86 | Denosumab - - Immunoglobulin G2 Human Monoclonal Antibody to RANK Ligand | 1件: Denosumab Denosumab | 1件: D03684
D03684
| 1件: TNFSF11 TNFSF11 💬 | 8件: Breast cancer Breast cancer, Chemical carcinogenesis - receptor activation, Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Osteoclast differentiation, Parathyroid hormone synthesis, secretion and action, Prolactin signaling pathway, Rheumatoid arthritis 💬 | 1件: 274 274 |
87 | Denosumab - Immunoglobulin G2 Human Monoclonal Antibody to RANK Ligand | 1件: Denosumab Denosumab | 1件: D03684
D03684
| 1件: TNFSF11 TNFSF11 💬 | 8件: Breast cancer Breast cancer, Chemical carcinogenesis - receptor activation, Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Osteoclast differentiation, Parathyroid hormone synthesis, secretion and action, Prolactin signaling pathway, Rheumatoid arthritis 💬 | 1件: 274 274 |
88 | Diclofenac sodium topical gel | 1件: Diclofenac Diclofenac (Synonym: Dipentocaine Topical Cream Compounding Kit) | 1件: D07816
D07816
| 2件: PTGS1 PTGS1, PTGS2 💬 | 23件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 13 13 |
89 | Diphtheria toxoid | 1件: Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) | - | - | - | 2件: 13 13, 46 |
90 | DP Mannitol (Synonym: Tobrex (TN)) | 1件: Mannitol Mannitol | 1件: D00062
D00062
(Name: Tobrex (TN)) | - | - | 1件: 299 299 |
91 | Dry powder tobramycin | 1件: Tobramycin Tobramycin | 1件: D00063
D00063
(Name: Tobramycin) | - | - | 1件: 299 299 |
92 | EGCG + Tocotrienol | 2件: Epigallocatechin gallate Epigallocatechin gallate, Tocotrienol | - | - | - | 1件: 299 299 |
93 | Essential amino acid intake + Leucine vs total AA supplement | 1件: Leucine Leucine | 1件: D00030
D00030
| - | - | 1件: 299 299 |
94 | Etanercepet, Rituximab, Abatacept, Tocilizumab, Sarilumab | 4件: Abatacept Abatacept, Rituximab, Sarilumab, Tocilizumab | 4件: D02596
D02596
(Name: Tocilizumab),
D02994
,
D03203
,
D10161
| 4件: CD80 CD80, CD86, IL6R, MS4A1 💬 | 25件: Allograft rejection Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Rheumatoid arthritis, Systemic lupus erythematosus, Th17 cell differentiation, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis, Viral protein interaction with cytokine and cytokine receptor, Virion - Adenovirus 💬 | 1件: 46 46 |
95 | Exposure to golimumab | 1件: Golimumab Golimumab | 1件: D04358
D04358
| 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 97 97 |
96 | Exposure to one or more disease-modifying drug(s)(DMDs) used to treat MS | - | - | - | - | 1件: 13 13 |
97 | Fluocinolone Acetonide (Synonym: FLUOCINOLONE ACETONIDE TOPICAL) | 2件: Fluocinolone Fluocinolone, Fluocinolone acetonide (Synonym: Fluocinolone Acetonide Topical) | 1件: D01825
D01825
(Name: FLUOCINOLONE ACETONIDE TOPICAL) | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 90 90 |
98 | Furosemide (Synonym: 14-PANEL TOXICOLOGY MEDICATED COLLECTION SYSTEM) | 1件: Furosemide Furosemide (Synonym: TOXYCOLOGY Medicated Collection System) | 1件: D00331
D00331
(Name: 14-PANEL TOXICOLOGY MEDICATED COLLECTION SYSTEM) | 1件: SLC12A2 SLC12A2 💬 | 3件: Pancreatic secretion Pancreatic secretion, Salivary secretion, Vibrio cholerae infection 💬 | 2件: 6 6, 86 |
99 | Furosemide Injection (Synonym: 14-PANEL TOXICOLOGY MEDICATED COLLECTION SYSTEM) | 1件: Furosemide Furosemide (Synonym: TOXYCOLOGY Medicated Collection System) | 1件: D00331
D00331
(Name: 14-PANEL TOXICOLOGY MEDICATED COLLECTION SYSTEM) | 1件: SLC12A2 SLC12A2 💬 | 3件: Pancreatic secretion Pancreatic secretion, Salivary secretion, Vibrio cholerae infection 💬 | 1件: 6 6 |
100 | Gamma-Tocopherol | 2件: Tocopherol Tocopherol, gamma-Tocopherol | 1件: D02332
D02332
(Name: Tocopherol) | - | - | 1件: 13 13 |
101 | GM-CSF, fosfomycin and metronidazole (Synonym: METRONIDAZOLE TOPICAL CREAM) | 2件: Fosfomycin Fosfomycin, Metronidazole (Synonym: Metronidazole Topical Gel) | 2件: D00409
D00409
(Name: METRONIDAZOLE TOPICAL CREAM),
D04253
| - | - | 1件: 97 97 |
102 | HAEMOPHILUS TYPE B CONJUGATE VACCINE (TETANUS TOXOID CONJUGATE) | 1件: Clostridium tetani toxoid antigen (formaldehyde inactivated) Clostridium tetani toxoid antigen (formaldehyde inactivated) | - | - | - | 2件: 13 13, 14 |
103 | HOV-12020 (Palm tocotrienols complex) | - | - | - | - | 1件: 124 124 |
104 | Human Monoclonal Antibody (CNTO 1275) to Interleukin 12p-40 | - | - | - | - | 1件: 96 96 |
105 | Human monoclonal antibody (CNTO 1275) to interleukin-12p40 | - | - | - | - | 1件: 13 13 |
106 | HUMAN SERUM ALBUMIN (HSA) FUSED TO RECOMBINANT HUMAN GROWTH HORMONE (HGH) | 2件: Albumin human Albumin human, Somatotropin | 1件: D02792
D02792
| - | - | 1件: 78 78 |
107 | Human Serum Albumin (HSA) fused to somatropin | 2件: Albumin human Albumin human, Somatotropin | 1件: D02792
D02792
| - | - | 1件: 78 78 |
108 | IDPM: Inhaled Dry Powder Mannitol (Synonym: Tobrex (TN)) | 1件: Mannitol Mannitol | 1件: D00062
D00062
(Name: Tobrex (TN)) | - | - | 1件: 299 299 |
109 | IDURONATE-2-SULFATASE FUSED TO A FC POLYPEPTIDE THAT BINDS TO THE HUMAN TRANSFERRIN RECEPTOR | - | - | - | - | 1件: 19 19 |
110 | Iloprost therapy up to 2 ng/kg x min | 1件: Iloprost Iloprost | 1件: D02721
D02721
| 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 51 51 |
111 | In double-blind phase: treatment with tofacitinib | 1件: Tofacitinib Tofacitinib | 1件: D09970
D09970
(Name: Tofacitinib) | 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 107 107 |
112 | In open-label phase: treatment with tofacitinib | 1件: Tofacitinib Tofacitinib | 1件: D09970
D09970
(Name: Tofacitinib) | 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 107 107 |
113 | Incobotulinum Toxin A | - | - | - | - | 3件: 2 2, 6, 13 |
114 | Inhaled Dry Powder Mannitol (Synonym: Tobrex (TN)) | 1件: Mannitol Mannitol | 1件: D00062
D00062
(Name: Tobrex (TN)) | - | - | 1件: 299 299 |
115 | Inhaled Mannitol (Synonym: Tobrex (TN)) | 1件: Mannitol Mannitol | 1件: D00062
D00062
(Name: Tobrex (TN)) | - | - | 1件: 299 299 |
116 | Inhaled tobramycin | 1件: Tobramycin Tobramycin | 1件: D00063
D00063
(Name: Tobramycin) | - | - | 1件: 299 299 |
117 | INN-Tocilizumab | 1件: Tocilizumab Tocilizumab | 1件: D02596
D02596
(Name: Tocilizumab) | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 266 266 |
118 | Insulin glargine (Synonym: TOUJEO) | 1件: Insulin glargine Insulin glargine (Synonym: Toujeo Solostar) | 1件: D03250
D03250
(Name: TOUJEO) | 1件: INSR INSR 💬 | 22件: AMPK signaling pathway AMPK signaling pathway, Adherens junction, Aldosterone-regulated sodium reabsorption, Alzheimer disease, Diabetic cardiomyopathy, FoxO signaling pathway, HIF-1 signaling pathway, Insulin resistance, Insulin signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, MAPK signaling pathway, Non-alcoholic fatty liver disease, Ovarian steroidogenesis, PI3K-Akt signaling pathway, Phospholipase D signaling pathway, Rap1 signaling pathway, Ras signaling pathway, Regulation of lipolysis in adipocytes, Type II diabetes mellitus, cGMP-PKG signaling pathway, mTOR signaling pathway 💬 | 1件: 299 299 |
119 | Interferon beta treatment to add-on atorvastatin treatment | 2件: Atorvastatin Atorvastatin, Human interferon beta | 1件: D07474
D07474
| 1件: HMGCR HMGCR 💬 | 4件: AMPK signaling pathway AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis 💬 | 1件: 13 13 |
120 | Intra-articular Tocilizumab | 1件: Tocilizumab Tocilizumab | 1件: D02596
D02596
(Name: Tocilizumab) | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 46 46 |
121 | Intradetrusor injection of Botulinum Toxin-A | - | - | - | - | 1件: 13 13 |
122 | Intravenous (i.v.) methylprednisolone 1000 mg, total 9 | 1件: Methylprednisolone Methylprednisolone | 1件: D00407
D00407
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 222 222 |
123 | Intravesical injection of Botulinum A toxin | - | - | - | - | 2件: 6 6, 17 |
124 | IPD® (suplatast tosilate) | - | - | - | - | 1件: 226 226 |
125 | Itraconazole (Synonym: TOLSURA) | 1件: Itraconazole Itraconazole (Synonym: Tolsura) | 1件: D00350
D00350
(Name: TOLSURA) | - | - | 6件: 3 3, 46, 65, 96, 227, 299 |
126 | Itraconazole 400 mg/day and terbinafine 500 mg/day administered orally. (Synonym: TOLSURA) | 2件: Itraconazole Itraconazole (Synonym: Tolsura), Terbinafine (Synonym: Terbinafine HCl Chlortimazole and Tolnaftate) | 2件: D00350
D00350
(Name: TOLSURA),
D02375
| - | - | 1件: 96 96 |
127 | Itraconazole/voriconazole (Synonym: TOLSURA) | 2件: Itraconazole Itraconazole (Synonym: Tolsura), Voriconazole | 2件: D00350
D00350
(Name: TOLSURA),
D00578
| - | - | 1件: 299 299 |
128 | Itraconazole? SHR0302 tablets (Synonym: TOLSURA) | 1件: Itraconazole Itraconazole (Synonym: Tolsura) | 1件: D00350
D00350
(Name: TOLSURA) | - | - | 1件: 46 46 |
129 | IV tobramycin | 1件: Tobramycin Tobramycin | 1件: D00063
D00063
(Name: Tobramycin) | - | - | 1件: 299 299 |
130 | Jinarc - Tolvaptan tablets | 1件: Tolvaptan Tolvaptan | 1件: D01213
D01213
(Name: Tolvaptan) | 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 |
131 | Ketorolac (Synonym: Toradol (TN)) | 1件: Ketorolac Ketorolac (Synonym: Toradol Tab 10mg) | 1件: D08104
D08104
(Name: Toradol (TN)) | 2件: PTGS1 PTGS1, PTGS2 💬 | 23件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 2件: 70 70, 226 |
132 | Ketorolac Tromethamine (Synonym: Toradol (TN)) | 2件: Ketorolac Ketorolac (Synonym: Toradol Tab 10mg), Tromethamine | 2件: D00396
D00396
,
D08104
(Name: Toradol (TN)) | 2件: PTGS1 PTGS1, PTGS2 💬 | 23件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 226 226 |
133 | Lentivirus-mediated delivery of ARSA to the CNS. | - | - | - | - | 1件: 19 19 |
134 | Listed for each disorder below, up to three drugs per disorder (too many characters to list in this field | - | - | - | - | 1件: 13 13 |
135 | LMX 4 Topical Cream | - | - | - | - | 1件: 256 256 |
136 | MabionCD20 (candidate biosimilar to rituximab) | 1件: Rituximab Rituximab | 1件: D02994
D02994
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 46 46 |
137 | Mannitol (Synonym: Tobrex (TN)) | 1件: Mannitol Mannitol | 1件: D00062
D00062
(Name: Tobrex (TN)) | - | - | 7件: 6 6, 13, 28, 60, 96, 113, 299 |
138 | Mannitol + pulmozyme (Synonym: Tobrex (TN)) | 2件: Dornase alfa Dornase alfa, Mannitol | 2件: D00062
D00062
(Name: Tobrex (TN)),
D03896
| - | - | 1件: 299 299 |
139 | Mannitol Inhalant Product (Synonym: Tobrex (TN)) | 1件: Mannitol Mannitol | 1件: D00062
D00062
(Name: Tobrex (TN)) | - | - | 1件: 299 299 |
140 | Mannitol inhalation powder (Synonym: Tobrex (TN)) | 1件: Mannitol Mannitol | 1件: D00062
D00062
(Name: Tobrex (TN)) | - | - | 1件: 299 299 |
141 | Medication to suppress the immune system | - | - | - | - | 1件: 19 19 |
142 | MENINGOCOCCAL GROUP A OLIGOSACCHARIDES CONJUGATED TO CORYNEBACTERIUM DIPHTHERIAE C7 (beta197) M8 (CRM197) PROTEIN | 2件: Corynebacterium diphtheriae Corynebacterium diphtheriae (Synonym: Tetanus and Diphtheria Toxoids Adsorbed), Corynebacterium diphtheriae CRM197 protein (Synonym: Diphtheria toxin mutant CRM197) | - | - | - | 1件: 11 11 |
143 | MENINGOCOCCAL GROUP A OLIGOSACCHARIDES CONJUGATED TO CORYNEBACTERIUM DIPHTHERIAE C7 (ß197) M8 (CRM197) PROTEIN | 2件: Corynebacterium diphtheriae Corynebacterium diphtheriae (Synonym: Tetanus and Diphtheria Toxoids Adsorbed), Corynebacterium diphtheriae CRM197 protein (Synonym: Diphtheria toxin mutant CRM197) | - | - | - | 1件: 11 11 |
144 | MENINGOCOCCAL GROUP W OLIGOSACCHARIDES CONJUGATED TO CORYNEBACTERIUM DIPHTHERIAE C7 (beta197) M8 (CRM197) PROTEIN | 2件: Corynebacterium diphtheriae Corynebacterium diphtheriae (Synonym: Tetanus and Diphtheria Toxoids Adsorbed), Corynebacterium diphtheriae CRM197 protein (Synonym: Diphtheria toxin mutant CRM197) | - | - | - | 1件: 11 11 |
145 | MENINGOCOCCAL GROUP W OLIGOSACCHARIDES CONJUGATED TO CORYNEBACTERIUM DIPHTHERIAE C7 (ß197) M8 (CRM197) PROTEIN | 2件: Corynebacterium diphtheriae Corynebacterium diphtheriae (Synonym: Tetanus and Diphtheria Toxoids Adsorbed), Corynebacterium diphtheriae CRM197 protein (Synonym: Diphtheria toxin mutant CRM197) | - | - | - | 1件: 11 11 |
146 | MENINGOCOCCAL GROUP Y OLIGOSACCHARIDES CONJUGATED TO CORYNEBACTERIUM DIPHTHERIAE C7 (Â197) M8 (CRM197) PROTEIN | 2件: Corynebacterium diphtheriae Corynebacterium diphtheriae (Synonym: Tetanus and Diphtheria Toxoids Adsorbed), Corynebacterium diphtheriae CRM197 protein (Synonym: Diphtheria toxin mutant CRM197) | - | - | - | 1件: 11 11 |
147 | Metformin 500 Mg Oral Tablet, up to 4 tablets a day | 1件: Metformin Metformin | 1件: D04966
D04966
| 2件: PRKAA1 PRKAA1, PRKAA2 💬 | 20件: AMPK signaling pathway AMPK signaling pathway, Adipocytokine signaling pathway, Alcoholic liver disease, Apelin signaling pathway, Autophagy - animal, Circadian rhythm, Fluid shear stress and atherosclerosis, FoxO signaling pathway, Glucagon signaling pathway, Hypertrophic cardiomyopathy, Insulin resistance, Insulin signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Non-alcoholic fatty liver disease, Oxytocin signaling pathway, PI3K-Akt signaling pathway, Thermogenesis, Tight junction, mTOR signaling pathway 💬 | 1件: 13 13 |
148 | METRONIDAZOLE (Synonym: METRONIDAZOLE TOPICAL CREAM) | 1件: Metronidazole Metronidazole (Synonym: Metronidazole Topical Gel) | 1件: D00409
D00409
(Name: METRONIDAZOLE TOPICAL CREAM) | - | - | 7件: 46 46, 51, 63, 94, 96, 97, 291 |
149 | Metronidazole capsule 50 mg (Synonym: METRONIDAZOLE TOPICAL CREAM) | 1件: Metronidazole Metronidazole (Synonym: Metronidazole Topical Gel) | 1件: D00409
D00409
(Name: METRONIDAZOLE TOPICAL CREAM) | - | - | 1件: 97 97 |
150 | Metronidazole Oral (Synonym: METRONIDAZOLE TOPICAL CREAM) | 1件: Metronidazole Metronidazole (Synonym: Metronidazole Topical Gel) | 1件: D00409
D00409
(Name: METRONIDAZOLE TOPICAL CREAM) | - | - | 1件: 96 96 |
151 | Midodrine or atomoxetine pill (Synonym: Tomoxetine) | 2件: Atomoxetine Atomoxetine (Synonym: Tomoxetine), Midodrine | 2件: D07473
D07473
(Name: Tomoxetine),
D08220
| 4件: ADRA1A ADRA1A, ADRA1B, ADRA1D, SLC6A2 💬 | 8件: AMPK signaling pathway AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Salivary secretion, Synaptic vesicle cycle, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 17 17 |
152 | Minibody against CD8 conjugated to desferrioxamine labeled with zirconium Zr 89 | 1件: Deferoxamine Deferoxamine | 1件: D03670
D03670
| - | - | 2件: 51 51, 53 |
153 | Mobilization of stem cells to prepare for Leukapheresis | - | - | - | - | 1件: 96 96 |
154 | Modified Oral Glucose Tolerance Test (50g 4-hours) | 1件: Dextrose, unspecified form Dextrose, unspecified form (Synonym: 100gm Glucose Tolerance Drink) | - | - | - | 1件: 299 299 |
155 | Most recent vaccine to seasonal influenza | - | - | - | - | 1件: 13 13 |
156 | MRA (Tocilizumab) | 1件: Tocilizumab Tocilizumab | 1件: D02596
D02596
(Name: Tocilizumab) | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 2件: 46 46, 107 |
157 | MRA(Tocilizumab) | 1件: Tocilizumab Tocilizumab | 1件: D02596
D02596
(Name: Tocilizumab) | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 2件: 46 46, 107 |
158 | MSC2430913A or ONO-4641 (to be used as synonyms) | - | - | - | - | 1件: 13 13 |
159 | MSC_NTF cells transplantation by multiple intramuscular injections at 24 separate sites, in addition to a single intrathechal injection into the CSF | - | - | - | - | 1件: 2 2 |
160 | Multiple (4 autologous subcutaneous T cell vaccinations with T cell lines reactive to nine myelin peptides) | 1件: Myelin basic protein Myelin basic protein | - | - | - | 1件: 13 13 |
161 | N. MENINGITIDIS GROUP C (STRAIN C11) OLIGOSACCHARIDE CONJUGATED TO | - | - | - | - | 1件: 11 11 |
162 | N. MENINGITIDIS GROUP C (STRAIN C11) OLIGOSACCHARIDE CONJUGATED TO CORYNEBACTERIUM DIPHTHERIAE CRM197 ADSORBED ON ALUMINUM HYDROXIDE | 5件: Aluminium Aluminium, Aluminum hydroxide (Synonym: Topcare Antacid Plus Anti Gas), Corynebacterium diphtheriae (Synonym: Tetanus and Diphtheria Toxoids Adsorbed), Corynebacterium diphtheriae CRM197 protein (Synonym: Diphtheria toxin mutant CRM197), Hydroxide ion | 1件: D02416
D02416
| - | - | 1件: 11 11 |
163 | Nanobody directed towards the human A1 domain of von Willebrand factor | 1件: Von Willebrand factor human Von Willebrand factor human | - | - | - | 1件: 64 64 |
164 | Nebcin (tobramycin) | 1件: Tobramycin Tobramycin | 1件: D00063
D00063
(Name: Tobramycin) | - | - | 1件: 299 299 |
165 | Nebcinal Tobi | - | - | - | - | 1件: 299 299 |
166 | Nebulization tobramycin | 1件: Tobramycin Tobramycin | 1件: D00063
D00063
(Name: Tobramycin) | - | - | 1件: 299 299 |
167 | NEISSERIA MENINGITIDIS GROUP A POLYSACCHARIDE CONJUGATED WITH TETANUS TOXOID CARRIER PROTEIN | 1件: Clostridium tetani toxoid antigen (formaldehyde inactivated) Clostridium tetani toxoid antigen (formaldehyde inactivated) | - | - | - | 1件: 50 50 |
168 | NEISSERIA MENINGITIDIS GROUP W-135 POLYSACCHARIDE CONJUGATED TO TETA | 1件: Triethylenetetramine Triethylenetetramine | - | - | - | 1件: 50 50 |
169 | NEISSERIA MENINGITIDIS GROUP W-135 POLYSACCHARIDE CONJUGATED TO TETANUS TOXOID CARRIER PROTEIN | 1件: Clostridium tetani toxoid antigen (formaldehyde inactivated) Clostridium tetani toxoid antigen (formaldehyde inactivated) | - | - | - | 1件: 50 50 |
170 | Onabotulinum Toxin A | - | - | - | - | 1件: 226 226 |
171 | OPC-41061 (tolvaptan) | 1件: Tolvaptan Tolvaptan | 1件: D01213
D01213
(Name: Tolvaptan) | 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 |
172 | Open Label Topical Beremagene Geperpavec (B-VEC) | - | - | - | - | 1件: 36 36 |
173 | Oral 5-ASA+/-topical 5-ASA+IV corticosteroids / PO Methylprednisolone | 2件: Mesalazine Mesalazine, Methylprednisolone | 2件: D00377
D00377
,
D00407
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 97 97 |
174 | Oral Glucose Tolerance test (75g 2-hour) | 1件: Dextrose, unspecified form Dextrose, unspecified form (Synonym: 100gm Glucose Tolerance Drink) | - | - | - | 1件: 299 299 |
175 | OSU 6162 similar to (-)-OSU 6162 | - | - | - | - | 1件: 6 6 |
176 | OSU6162 similar to (-)-OSU 6162 | - | - | - | - | 2件: 6 6, 8 |
177 | Outer membrane vesicles (OMV) from Neisseria meningitidis group B strain NZ98/254measured as amount of total protein containing the PorA P1.4 | - | - | - | - | 1件: 11 11 |
178 | Oxybutynin, tolterodine, solifenacin | 3件: Oxybutynin Oxybutynin, Solifenacin, Tolterodine | 3件: D00465
D00465
,
D00646
(Name: Tolterodine),
D08522
| 5件: CHRM1 CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 💬 | 13件: Alzheimer disease Alzheimer disease, Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway 💬 | 1件: 53 53 |
179 | Patients will be randomized to receive EHP-101 | - | - | - | - | 1件: 51 51 |
180 | Pertussis toxoid | 1件: Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) | - | - | - | 1件: 46 46 |
181 | PERTUSSIS TOXOID ADSORBED ON ALUMINIUM HYDROXIDE | 4件: Aluminium Aluminium, Aluminum hydroxide (Synonym: Topcare Antacid Plus Anti Gas), Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated), Hydroxide ion | 1件: D02416
D02416
| - | - | 1件: 46 46 |
182 | Pharmacologic approaches to glycemic treatment | - | - | - | - | 1件: 298 298 |
183 | Phentermine-Topiramate | 2件: Phentermine Phentermine, Topiramate | 2件: D00537
D00537
(Name: Topiramate),
D05458
| 41件: CA2 CA2, CA4, CACNA1C, CACNA1D, CACNA1F, CACNA1S, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GRIA1, GRIA2, GRIA3, GRIA4, GRIK1, GRIK2, GRIK3, GRIK4, GRIK5, MAOA, MAOB, SCN1A, SCN2A, SCN3A, SCN5A, SCN9A, SLC6A2, SLC6A3, SLC6A4 💬 | 63件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Alcoholism, Aldosterone synthesis and secretion, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Arginine and proline metabolism, Arrhythmogenic right ventricular cardiomyopathy, Bile secretion, Calcium signaling pathway, Carbohydrate digestion and absorption, Cardiac muscle contraction, Cellular senescence, Chemical carcinogenesis - receptor activation, Cholinergic synapse, Circadian entrainment, Cocaine addiction, Collecting duct acid secretion, Cortisol synthesis and secretion, Cushing syndrome, Dilated cardiomyopathy, Dopaminergic synapse, Drug metabolism - cytochrome P450, GABAergic synapse, Gastric acid secretion, Glutamatergic synapse, Glycine, serine and threonine metabolism, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Histidine metabolism, Huntington disease, Hypertrophic cardiomyopathy, Insulin secretion, Long-term depression, Long-term potentiation, MAPK signaling pathway, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Nitrogen metabolism, Oxytocin signaling pathway, Pancreatic secretion, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Phenylalanine metabolism, Prion disease, Proximal tubule bicarbonate reclamation, Renin secretion, Retrograde endocannabinoid signaling, Serotonergic synapse, Spinocerebellar ataxia, Synaptic vesicle cycle, Taste transduction, Tight junction, Transcriptional misregulation in cancer, Tryptophan metabolism, Type II diabetes mellitus, Tyrosine metabolism, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 97 97 |
184 | PLA + MTX switched to ABA+ MTX, DB | - | - | - | - | 1件: 46 46 |
185 | PNEUMOCOCCAL POLYSACCHARIDE CONJUGATE VACCINE (13-VALENT, ADSORBED) CONJUGATED TO CRM197 CARRIER PROTEIN AND ADSORBED ON ALUMINIUM PHOSPHATE | 4件: Aluminium Aluminium, Aluminium phosphate, Corynebacterium diphtheriae CRM197 protein (Synonym: Diphtheria toxin mutant CRM197), Phosphate ion | - | - | - | 1件: 46 46 |
186 | Positron Emission Tomography using [11 Carbon]-3-amino-4-(2-dimethylaminomethylphenylsulfanyl)-benzonitrile ([11C]-DASB) and [18 Fluorine]-altanserin ([18F]-altanserin) | 1件: Activated charcoal Activated charcoal | - | - | - | 1件: 6 6 |
187 | Positron Emission Tomography using [18 Fluorine]-altanserin ([18F]-altanserin) | - | - | - | - | 1件: 6 6 |
188 | Previously referred to as MEDI2070 and AMG 139 | - | - | - | - | 2件: 96 96, 97 |
189 | Previously referred to as MEDI2070 and AMG 139, AGN-151-598 | - | - | - | - | 1件: 96 96 |
190 | PXT3003 Dose 2 (equivalent to twice Dose 1) | - | - | - | - | 1件: 10 10 |
191 | QR-313 Gel for Topical (Cutaneous) Administration | - | - | - | - | 1件: 36 36 |
192 | Rapamycin cream, topical, 0.5%, 1.0% w/w | 1件: Sirolimus Sirolimus | 1件: D00753
D00753
| 1件: MTOR MTOR 💬 | 51件: AMPK signaling pathway AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬 | 1件: 158 158 |
193 | RECOMBINANT HUMAN ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 FUSED TO THE FC FRAGMENT OF IGG1 | - | - | - | - | 1件: 166 166 |
194 | Recombinant human monoclonal antibody to human IL-1Beta of the IgG1/K class | - | - | - | - | 3件: 106 106, 107, 108 |
195 | Recombinant human monoclonal antibody to Il-17 of the IgG1-k-class | - | - | - | - | 1件: 271 271 |
196 | Recombinant human monoclonal antibody to inerleukin-1beta of the IgG1-K-class | - | - | - | - | 1件: 46 46 |
197 | Recombinant human monoclonal antibody to interleukin-1beta of the IgG1-Kappa-class | - | - | - | - | 1件: 46 46 |
198 | RECOMBINANT HUMAN SERUM ALBUMIN (HSA) FUSED TO HUMAN GROWTH HORMONE (HGH) | 2件: Albumin human Albumin human, Somatotropin | 1件: D02792
D02792
| - | - | 1件: 78 78 |
199 | Recombinant humanized monoclonal antibody omalizumab to IgE | 1件: Omalizumab Omalizumab | 1件: D05251
D05251
| 1件: FCER1A FCER1A 💬 | 4件: Asthma Asthma, Fc epsilon RI signaling pathway, Phospholipase D signaling pathway, Sphingolipid signaling pathway 💬 | 1件: 299 299 |
200 | Reduced Toxicity Ablative Regimen | - | - | - | - | 3件: 62 62, 65, 284 |
201 | Response to anakinra associated with methotrexate | 2件: Anakinra Anakinra, Methotrexate | 2件: D00142
D00142
,
D02934
| 4件: DHFR DHFR, DHFR2, IL1R1, IL1R2 💬 | 20件: Amoebiasis Amoebiasis, Antifolate resistance, Biosynthesis of cofactors, Cytokine-cytokine receptor interaction, Fluid shear stress and atherosclerosis, Folate biosynthesis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Inflammatory mediator regulation of TRP channels, MAPK signaling pathway, Metabolic pathways, NF-kappa B signaling pathway, One carbon pool by folate, Osteoclast differentiation, Pathogenic Escherichia coli infection, Prostate cancer, Shigellosis, Th17 cell differentiation, Transcriptional misregulation in cancer 💬 | 1件: 46 46 |
202 | Response to infliximab associated with methotrexate | 2件: Infliximab Infliximab, Methotrexate | 2件: D00142
D00142
,
D02598
| 3件: DHFR DHFR, DHFR2, TNF 💬 | 71件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, Biosynthesis of cofactors, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Folate biosynthesis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, Metabolic pathways, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, One carbon pool by folate, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 |
203 | RhumAb to Il-17A (IgG1-k-class) | - | - | - | - | 4件: 13 13, 46, 56, 96 |
204 | RhumAb to Il-17A (IgG1-k-class) rhumAb to Il-17A (IgG1-k-class) | - | - | - | - | 1件: 96 96 |
205 | RhumAb to IL-17A igG1-k-class | - | - | - | - | 1件: 13 13 |
206 | RoActemra/Actemra (tocilizumab) | 1件: Tocilizumab Tocilizumab | 1件: D02596
D02596
(Name: Tocilizumab) | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 107 107 |
207 | RPC1063 (equivalent to ozanimod | 1件: Ozanimod Ozanimod | 1件: D10968
D10968
| 5件: S1PR1 S1PR1, S1PR2, S1PR3, S1PR4, S1PR5 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 96 96 |
208 | RPC1063 (equivalent to ozanimod HCl) | 1件: Ozanimod Ozanimod | 1件: D10968
D10968
| 5件: S1PR1 S1PR1, S1PR2, S1PR3, S1PR4, S1PR5 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 96 96 |
209 | RPC1063 equiv to ozanimod HCI | 1件: Ozanimod Ozanimod | 1件: D10968
D10968
| 5件: S1PR1 S1PR1, S1PR2, S1PR3, S1PR4, S1PR5 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 96 96 |
210 | RPC1063 equiv. to ozanimod HCI | 1件: Ozanimod Ozanimod | 1件: D10968
D10968
| 5件: S1PR1 S1PR1, S1PR2, S1PR3, S1PR4, S1PR5 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 96 96 |
211 | SB2 (proposed biosimilar to infliximab) | 1件: Infliximab Infliximab | 1件: D02598
D02598
| 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 |
212 | SB4 (proposed biosimilar to etanercept) | 1件: Etanercept Etanercept | 1件: D00742
D00742
| 2件: LTA LTA, TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 |
213 | SB5 (proposed biosimilar to adalimumab) | 1件: Adalimumab Adalimumab | 1件: D02597
D02597
| 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 |
214 | Sorafenib (as tosylate) | 1件: Sorafenib Sorafenib (Synonym: Sorafenib Tosylate) | 1件: D08524
D08524
| 8件: BRAF BRAF, FLT3, FLT4, KDR, KIT, PDGFRB, RAF1, RET 💬 | 89件: Acute myeloid leukemia Acute myeloid leukemia, Alcoholism, Alzheimer disease, Apelin signaling pathway, Apoptosis, Autophagy - animal, Axon guidance, B cell receptor signaling pathway, Bladder cancer, Breast cancer, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Choline metabolism in cancer, Chronic myeloid leukemia, Colorectal cancer, Cushing syndrome, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endometrial cancer, ErbB signaling pathway, Estrogen signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Fluid shear stress and atherosclerosis, Focal adhesion, FoxO signaling pathway, Gap junction, Gastric cancer, Glioma, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Hepatocellular carcinoma, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Influenza A, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Long-term depression, Long-term potentiation, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Natural killer cell mediated cytotoxicity, Neurotrophin signaling pathway, Neutrophil extracellular trap formation, Non-small cell lung cancer, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Relaxin signaling pathway, Renal cell carcinoma, Salmonella infection, Serotonergic synapse, Signaling pathways regulating pluripotency of stem cells, Sphingolipid signaling pathway, T cell receptor signaling pathway, Thyroid cancer, Thyroid hormone signaling pathway, Transcriptional misregulation in cancer, Tuberculosis, VEGF signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway, mTOR signaling pathway 💬 | 1件: 34 34 |
215 | Subcutaneous tocilizumab | 1件: Tocilizumab Tocilizumab | 1件: D02596
D02596
(Name: Tocilizumab) | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 46 46 |
216 | Subcutaneous tocilizumab 162mg/biweekly | 1件: Tocilizumab Tocilizumab | 1件: D02596
D02596
(Name: Tocilizumab) | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 46 46 |
217 | Suplatast tosilate | - | - | - | - | 1件: 226 226 |
218 | Switch to Myfortic | 1件: Mycophenolic acid Mycophenolic acid | 1件: D05096
D05096
| 2件: IMPDH1 IMPDH1, IMPDH2 💬 | 4件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism, Purine metabolism 💬 | 1件: 49 49 |
219 | Takecab tablets + amoxicillin + clarithromycin (first-line eradication) Takecab tablets + amoxicillin + metronidazole (second-line eradication) (Synonym: METRONIDAZOLE TOPICAL CREAM) | 3件: Amoxicillin Amoxicillin, Clarithromycin, Metronidazole (Synonym: Metronidazole Topical Gel) | 4件: D00229
D00229
,
D00276
,
D00409
(Name: METRONIDAZOLE TOPICAL CREAM),
D07452
| - | - | 1件: 63 63 |
220 | Tedizolid (Synonym: Torezolid) | 1件: Tedizolid Tedizolid (Synonym: Torezolid) | 1件: D09685
D09685
(Name: Torezolid) | - | - | 1件: 299 299 |
221 | Tedizolid IV (Synonym: Torezolid) | 1件: Tedizolid Tedizolid (Synonym: Torezolid) | 1件: D09685
D09685
(Name: Torezolid) | - | - | 1件: 299 299 |
222 | Tedizolid PO (Synonym: Torezolid) | 1件: Tedizolid Tedizolid (Synonym: Torezolid) | 1件: D09685
D09685
(Name: Torezolid) | - | - | 1件: 299 299 |
223 | Temsirolimus (Synonym: Torisel (TN)) | 1件: Temsirolimus Temsirolimus (Synonym: Torisel) | 1件: D06068
D06068
(Name: Torisel (TN)) | 1件: MTOR MTOR 💬 | 51件: AMPK signaling pathway AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬 | 1件: 13 13 |
224 | Temsirolimus Tablets (Synonym: Torisel (TN)) | 1件: Temsirolimus Temsirolimus (Synonym: Torisel) | 1件: D06068
D06068
(Name: Torisel (TN)) | 1件: MTOR MTOR 💬 | 51件: AMPK signaling pathway AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬 | 1件: 13 13 |
225 | Teriparatide conjugated to a multiarm polyethylene glycol carrier molecule through a cleava | 2件: Polyethylene glycol Polyethylene glycol (Synonym: Topcare ClearLax), Teriparatide | 2件: D03370
D03370
,
D06078
| 1件: PTH1R PTH1R 💬 | 3件: Endocrine and other factor-regulated calcium reabsorption Endocrine and other factor-regulated calcium reabsorption, Neuroactive ligand-receptor interaction, Parathyroid hormone synthesis, secretion and action 💬 | 1件: 235 235 |
226 | Teriparatide conjugated to a multiarm polyethylene glycol carrier molecule through a cleavable linker | 2件: Polyethylene glycol Polyethylene glycol (Synonym: Topcare ClearLax), Teriparatide | 2件: D03370
D03370
,
D06078
| 1件: PTH1R PTH1R 💬 | 3件: Endocrine and other factor-regulated calcium reabsorption Endocrine and other factor-regulated calcium reabsorption, Neuroactive ligand-receptor interaction, Parathyroid hormone synthesis, secretion and action 💬 | 1件: 235 235 |
227 | Tetanus diphtheria toxoid vaccine (Td) | 1件: Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) | - | - | - | 1件: 13 13 |
228 | Tetanus diphtheria toxoids vaccine | - | - | - | - | 1件: 13 13 |
229 | Tetanus toxoid | 1件: Clostridium tetani toxoid antigen (formaldehyde inactivated) Clostridium tetani toxoid antigen (formaldehyde inactivated) | - | - | - | 4件: 13 13, 14, 46, 50 |
230 | Tetanus toxoid (TT) containing vaccine (Td, Tdap) | 1件: Clostridium tetani toxoid antigen (formaldehyde inactivated) Clostridium tetani toxoid antigen (formaldehyde inactivated) | - | - | - | 1件: 13 13 |
231 | Tetanus toxoid adsorbed | 1件: Clostridium tetani toxoid antigen (formaldehyde inactivated) Clostridium tetani toxoid antigen (formaldehyde inactivated) | - | - | - | 1件: 46 46 |
232 | Tetanus toxoid adsorbed booster vaccine | 1件: Clostridium tetani toxoid antigen (formaldehyde inactivated) Clostridium tetani toxoid antigen (formaldehyde inactivated) | - | - | - | 1件: 46 46 |
233 | Tetanus Toxoid Adsorbed Vaccine | 1件: Clostridium tetani toxoid antigen (formaldehyde inactivated) Clostridium tetani toxoid antigen (formaldehyde inactivated) | - | - | - | 1件: 46 46 |
234 | Tetanus toxoid vaccine | 1件: Clostridium tetani toxoid antigen (formaldehyde inactivated) Clostridium tetani toxoid antigen (formaldehyde inactivated) | - | - | - | 1件: 13 13 |
235 | Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed) | 3件: Clostridium tetani toxoid antigen (formaldehyde inactivated) Clostridium tetani toxoid antigen (formaldehyde inactivated), Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated), Pertussis vaccine (Synonym: Diphtheria and Tetanus Toxoids With Pertussis Vaccine Adsorbed) | 1件: D06514
D06514
| - | - | 1件: 46 46 |
236 | The investigational medicinal product (IMP) will be labeled as PF-04236921 106 mg/vial, Clonal SC lyophilized form, which is equivalent to PF-04236921 Powder for Injection, 106 mg/vial as described in the enclosed CTA | - | - | - | - | 1件: 96 96 |
237 | The investigational medicinal product (IMP) will be labeled as PF-04236921 106 mg/vial, Clonal SC lyophilized form, which is equivalent to PF-04236921 Powder for Injection, 106 mg/vial as described in the enclosed CTA. | - | - | - | - | 1件: 96 96 |
238 | Time delay treatment of botulinum toxin | - | - | - | - | 1件: 149 149 |
239 | TIP (Tobramycin inhalation powder) | 1件: Tobramycin Tobramycin | 1件: D00063
D00063
(Name: Tobramycin) | - | - | 1件: 299 299 |
240 | TIS (Tobramycin Inhalation Solution) | 1件: Tobramycin Tobramycin | 1件: D00063
D00063
(Name: Tobramycin) | - | - | 1件: 299 299 |
241 | TO | - | - | - | - | 1件: 6 6 |
242 | To be confirmed | - | - | - | - | 3件: 46 46, 65, 97 |
243 | To be determined | - | - | - | - | 2件: 96 96, 113 |
244 | To be requested | - | - | - | - | 2件: 96 96, 97 |
245 | TOBI | - | - | - | - | 1件: 299 299 |
246 | TOBI (tobramycin) | 1件: Tobramycin Tobramycin | 1件: D00063
D00063
(Name: Tobramycin) | - | - | 1件: 299 299 |
247 | TOBI 300 mg / 5 mL nebuliser solution | 1件: Tobramycin Tobramycin | 1件: D00063
D00063
(Name: Tobramycin) | - | - | 1件: 299 299 |
248 | TOBI 300 mg/5 ml Lösung für einen | 1件: Tobramycin Tobramycin | 1件: D00063
D00063
(Name: Tobramycin) | - | - | 1件: 299 299 |
249 | TOBI 300 mg/5 ml Lösung für einen Vernebler | 1件: Tobramycin Tobramycin | 1件: D00063
D00063
(Name: Tobramycin) | - | - | 1件: 299 299 |
250 | TOBI 300 mg/5 ml Nebuliser Solution | 1件: Tobramycin Tobramycin | 1件: D00063
D00063
(Name: Tobramycin) | - | - | 1件: 299 299 |
251 | TOBI 300 mg/5 ml solución para inhalación por nebulizador | 1件: Tobramycin Tobramycin | 1件: D00063
D00063
(Name: Tobramycin) | - | - | 1件: 299 299 |
252 | TOBI 300 mg/5 ml, solution pour inhalation par nébuliseur | 1件: Tobramycin Tobramycin | 1件: D00063
D00063
(Name: Tobramycin) | - | - | 1件: 299 299 |
253 | TOBI 300mg/ 5ml solución para inhalación con nebulizador | 1件: Tobramycin Tobramycin | 1件: D00063
D00063
(Name: Tobramycin) | - | - | 1件: 299 299 |
254 | TOBI 300mg/5mL Nebuliser Solution | 1件: Tobramycin Tobramycin | 1件: D00063
D00063
(Name: Tobramycin) | - | - | 1件: 299 299 |
255 | Tobi 300mg/5ml Nebuliser solution. | 1件: Tobramycin Tobramycin | 1件: D00063
D00063
(Name: Tobramycin) | - | - | 1件: 299 299 |
256 | Tobi 300mg/5ml Solución para inhalación por nebulizador. | 1件: Tobramycin Tobramycin | 1件: D00063
D00063
(Name: Tobramycin) | - | - | 1件: 299 299 |
257 | Tobi Inhalant Product | 1件: Tobramycin Tobramycin | 1件: D00063
D00063
(Name: Tobramycin) | - | - | 1件: 299 299 |
258 | Tobi Nebcinal | - | - | - | - | 1件: 299 299 |
259 | TOBI PODHALER | - | - | - | - | 1件: 299 299 |
260 | TOBI PODHALER - 28 MG POLVERE PER INALAZIONE CAPSULA RIGIDA USO INALATORIO BLISTER(ALU/ALU) 56 CAPSULE + 1 INALATORE | 1件: Tobramycin Tobramycin | 1件: D00063
D00063
(Name: Tobramycin) | - | - | 1件: 299 299 |
261 | TOBI Podhaler 28 mg Hartkapseln mit Pulver zur Inhalation | 1件: Tobramycin Tobramycin | 1件: D00063
D00063
(Name: Tobramycin) | - | - | 1件: 299 299 |
262 | TOBI Podhaler 28 mg inhalációs por, kemény kapszula | 1件: Tobramycin Tobramycin | 1件: D00063
D00063
(Name: Tobramycin) | - | - | 1件: 299 299 |
263 | TOBI PODHALER*448CPS 28MG+10IN | 1件: Tobramycin Tobramycin | 1件: D00063
D00063
(Name: Tobramycin) | - | - | 1件: 299 299 |
264 | TOBI*NEBUL 56F 1D 300MG/5ML | 1件: Tobramycin Tobramycin | 1件: D00063
D00063
(Name: Tobramycin) | - | - | 1件: 299 299 |
265 | TOBI® | 1件: Tobramycin Tobramycin | 1件: D00063
D00063
(Name: Tobramycin) | - | - | 1件: 299 299 |
266 | TOBI™ Podhaler™ 112 mg inhaled twice daily | - | - | - | - | 1件: 299 299 |
267 | Tobramcyin | - | - | - | - | 1件: 299 299 |
268 | TOBRAMICINA | 1件: Tobramycin Tobramycin | 1件: D00063
D00063
(Name: Tobramycin) | - | - | 1件: 299 299 |
269 | Tobramicina polvere inalatoria | 1件: Tobramycin Tobramycin | 1件: D00063
D00063
(Name: Tobramycin) | - | - | 1件: 299 299 |
270 | TOBRAMICINA SOLFATO | 1件: Tobramycin Tobramycin | 1件: D00063
D00063
(Name: Tobramycin) | - | - | 1件: 299 299 |
271 | Tobramicyn | - | - | - | - | 1件: 299 299 |
272 | TOBRAMYCIN | 1件: Tobramycin Tobramycin | 1件: D00063
D00063
(Name: Tobramycin) | - | - | 1件: 299 299 |
273 | Tobramycin (Gernebcin®) | 1件: Tobramycin Tobramycin | 1件: D00063
D00063
(Name: Tobramycin) | - | - | 1件: 299 299 |
274 | Tobramycin / Bramitob | 1件: Tobramycin Tobramycin | 1件: D00063
D00063
(Name: Tobramycin) | - | - | 1件: 299 299 |
275 | Tobramycin / TOBI | 1件: Tobramycin Tobramycin | 1件: D00063
D00063
(Name: Tobramycin) | - | - | 1件: 299 299 |
276 | Tobramycin 100 PARI | 1件: Tobramycin Tobramycin | 1件: D00063
D00063
(Name: Tobramycin) | - | - | 1件: 299 299 |
277 | Tobramycin dry powder | 1件: Tobramycin Tobramycin | 1件: D00063
D00063
(Name: Tobramycin) | - | - | 1件: 299 299 |
278 | Tobramycin for Inhalation | 1件: Tobramycin Tobramycin | 1件: D00063
D00063
(Name: Tobramycin) | - | - | 1件: 299 299 |
279 | Tobramycin Inhalation Powder | 1件: Tobramycin Tobramycin | 1件: D00063
D00063
(Name: Tobramycin) | - | - | 1件: 299 299 |
280 | Tobramycin Inhalation Powder (TIP) | 1件: Tobramycin Tobramycin | 1件: D00063
D00063
(Name: Tobramycin) | - | - | 1件: 299 299 |
281 | Tobramycin Inhalation Powder TIP delivered by the T-326 Inhaler | 1件: Tobramycin Tobramycin | 1件: D00063
D00063
(Name: Tobramycin) | - | - | 1件: 299 299 |
282 | Tobramycin inhalation solution | 1件: Tobramycin Tobramycin | 1件: D00063
D00063
(Name: Tobramycin) | - | - | 1件: 299 299 |
283 | Tobramycin Inhalation Solution (TIS) | 1件: Tobramycin Tobramycin | 1件: D00063
D00063
(Name: Tobramycin) | - | - | 1件: 299 299 |
284 | Tobramycin inhalation solution using a PARI LC® Plus nebulizer. | 1件: Tobramycin Tobramycin | 1件: D00063
D00063
(Name: Tobramycin) | - | - | 1件: 299 299 |
285 | Tobramycin injection 40mg/1ml | 1件: Tobramycin Tobramycin | 1件: D00063
D00063
(Name: Tobramycin) | - | - | 1件: 299 299 |
286 | Tobramycin nebulized nasally | 1件: Tobramycin Tobramycin | 1件: D00063
D00063
(Name: Tobramycin) | - | - | 1件: 299 299 |
287 | Tobramycin Powder | 1件: Tobramycin Tobramycin | 1件: D00063
D00063
(Name: Tobramycin) | - | - | 1件: 299 299 |
288 | Tobramycin Solution for Inhalation | 1件: Tobramycin Tobramycin | 1件: D00063
D00063
(Name: Tobramycin) | - | - | 1件: 299 299 |
289 | Tobramycin solution for inhalation (TOBI) | 1件: Tobramycin Tobramycin | 1件: D00063
D00063
(Name: Tobramycin) | - | - | 1件: 299 299 |
290 | Tobramycin solution for inhalation 300 mg | 1件: Tobramycin Tobramycin | 1件: D00063
D00063
(Name: Tobramycin) | - | - | 1件: 299 299 |
291 | Tobramycin Steri-Neb 300 mg/5 ml, inhalation solution | 1件: Tobramycin Tobramycin | 1件: D00063
D00063
(Name: Tobramycin) | - | - | 1件: 299 299 |
292 | TOBRAMYCIN SULFATE | 2件: Sulfate ion Sulfate ion, Tobramycin | 1件: D00063
D00063
(Name: Tobramycin) | - | - | 1件: 299 299 |
293 | Tobramycine | 1件: Tobramycin Tobramycin | 1件: D00063
D00063
(Name: Tobramycin) | - | - | 1件: 299 299 |
294 | Tobramycinum | 1件: Tobramycin Tobramycin | 1件: D00063
D00063
(Name: Tobramycin) | - | - | 1件: 299 299 |
295 | Tobrineb/Bramitob | - | - | - | - | 1件: 299 299 |
296 | Tocilizmab | - | - | - | - | 1件: 46 46 |
297 | Tocilizumab | 1件: Tocilizumab Tocilizumab | 1件: D02596
D02596
(Name: Tocilizumab) | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 21件: 2 2, 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 |
298 | Tocilizumab (Actemra or RoActemra) | 1件: Tocilizumab Tocilizumab | 1件: D02596
D02596
(Name: Tocilizumab) | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 46 46 |
299 | Tocilizumab (Actemra) | 1件: Tocilizumab Tocilizumab | 1件: D02596
D02596
(Name: Tocilizumab) | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 46 46 |
300 | Tocilizumab (Actemra®) | 1件: Tocilizumab Tocilizumab | 1件: D02596
D02596
(Name: Tocilizumab) | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 46 46 |
301 | Tocilizumab (MRA-SC) | 1件: Tocilizumab Tocilizumab | 1件: D02596
D02596
(Name: Tocilizumab) | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 40 40 |
302 | Tocilizumab (TCZ) | 1件: Tocilizumab Tocilizumab | 1件: D02596
D02596
(Name: Tocilizumab) | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 2件: 46 46, 56 |
303 | Tocilizumab + Glucocorticoids (GCs) | 1件: Tocilizumab Tocilizumab | 1件: D02596
D02596
(Name: Tocilizumab) | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 41 41 |
304 | Tocilizumab + methotrexate(MTX) | 2件: Methotrexate Methotrexate, Tocilizumab | 2件: D00142
D00142
,
D02596
(Name: Tocilizumab) | 3件: DHFR DHFR, DHFR2, IL6R 💬 | 17件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, Folate biosynthesis, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Metabolic pathways, Non-alcoholic fatty liver disease, One carbon pool by folate, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 46 46 |
305 | Tocilizumab 162 mg | 1件: Tocilizumab Tocilizumab | 1件: D02596
D02596
(Name: Tocilizumab) | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 46 46 |
306 | Tocilizumab 162Mg/0.9Ml Autoinjector | 1件: Tocilizumab Tocilizumab | 1件: D02596
D02596
(Name: Tocilizumab) | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 41 41 |
307 | Tocilizumab 162mg/0.9ml jeringa SC | 1件: Tocilizumab Tocilizumab | 1件: D02596
D02596
(Name: Tocilizumab) | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 46 46 |
308 | Tocilizumab 162mg/0.9ml SC PFS SC | 1件: Tocilizumab Tocilizumab | 1件: D02596
D02596
(Name: Tocilizumab) | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 46 46 |
309 | Tocilizumab 162mg/0.9ml syringe SC | 1件: Tocilizumab Tocilizumab | 1件: D02596
D02596
(Name: Tocilizumab) | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 46 46 |
310 | Tocilizumab [RoActemra/Actemra] | 1件: Tocilizumab Tocilizumab | 1件: D02596
D02596
(Name: Tocilizumab) | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 4件: 46 46, 51, 107, 331 |
311 | Tocilizumab [RoActemra] | 1件: Tocilizumab Tocilizumab | 1件: D02596
D02596
(Name: Tocilizumab) | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 46 46 |
312 | Tocilizumab and IV steroids combination | 1件: Tocilizumab Tocilizumab | 1件: D02596
D02596
(Name: Tocilizumab) | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 41 41 |
313 | Tocilizumab Infusion RoAcemtra (EU) | 1件: Tocilizumab Tocilizumab | 1件: D02596
D02596
(Name: Tocilizumab) | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 266 266 |
314 | Tocilizumab Injectable Product | 1件: Tocilizumab Tocilizumab | 1件: D02596
D02596
(Name: Tocilizumab) | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 11 11 |
315 | Tocilizumab Injection | 1件: Tocilizumab Tocilizumab | 1件: D02596
D02596
(Name: Tocilizumab) | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 13 13 |
316 | Tocilizumab Injection 8mg/kg | 1件: Tocilizumab Tocilizumab | 1件: D02596
D02596
(Name: Tocilizumab) | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 46 46 |
317 | Tocilizumab IV | 1件: Tocilizumab Tocilizumab | 1件: D02596
D02596
(Name: Tocilizumab) | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 46 46 |
318 | Tocilizumab plus methotrexate | 2件: Methotrexate Methotrexate, Tocilizumab | 2件: D00142
D00142
,
D02596
(Name: Tocilizumab) | 3件: DHFR DHFR, DHFR2, IL6R 💬 | 17件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, Folate biosynthesis, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Metabolic pathways, Non-alcoholic fatty liver disease, One carbon pool by folate, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 46 46 |
319 | Tocilizumab Prefilled Syringe | 1件: Tocilizumab Tocilizumab | 1件: D02596
D02596
(Name: Tocilizumab) | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 2件: 41 41, 46 |
320 | Tocilizumab Roche | 1件: Tocilizumab Tocilizumab | 1件: D02596
D02596
(Name: Tocilizumab) | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 2件: 46 46, 107 |
321 | TOCILIZUMAB SC | 1件: Tocilizumab Tocilizumab | 1件: D02596
D02596
(Name: Tocilizumab) | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 3件: 41 41, 46, 107 |
322 | Tocilizumab SC 162 mg/0.9 ml disposable auto-injector (AI) | 1件: Tocilizumab Tocilizumab | 1件: D02596
D02596
(Name: Tocilizumab) | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 46 46 |
323 | Tocilizumab SC 162 mg/0.9 ml pre-filled syringe with safety device (PFS) | 1件: Tocilizumab Tocilizumab | 1件: D02596
D02596
(Name: Tocilizumab) | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 46 46 |
324 | Tocilizumab SC 162 mg/0.9 ml prefilled syringe with safety device (PFS) | 1件: Tocilizumab Tocilizumab | 1件: D02596
D02596
(Name: Tocilizumab) | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 51 51 |
325 | Tocilizumab treatment | 1件: Tocilizumab Tocilizumab | 1件: D02596
D02596
(Name: Tocilizumab) | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 41 41 |
326 | Tocilizumab+Methotrexate(MTX) | 2件: Methotrexate Methotrexate, Tocilizumab | 2件: D00142
D00142
,
D02596
(Name: Tocilizumab) | 3件: DHFR DHFR, DHFR2, IL6R 💬 | 17件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, Folate biosynthesis, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Metabolic pathways, Non-alcoholic fatty liver disease, One carbon pool by folate, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 46 46 |
327 | Tocilizumab, Abatacept | 2件: Abatacept Abatacept, Tocilizumab | 2件: D02596
D02596
(Name: Tocilizumab),
D03203
| 3件: CD80 CD80, CD86, IL6R 💬 | 25件: Allograft rejection Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Rheumatoid arthritis, Systemic lupus erythematosus, Th17 cell differentiation, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis, Viral protein interaction with cytokine and cytokine receptor, Virion - Adenovirus 💬 | 1件: 46 46 |
328 | Tocilizumabum | - | - | - | - | 1件: 46 46 |
329 | Tociluzumab | - | - | - | - | 1件: 65 65 |
330 | Tocoferol | 1件: Tocopherol Tocopherol | 1件: D02332
D02332
(Name: Tocopherol) | - | - | 1件: 90 90 |
331 | Tocopherol | 1件: Tocopherol Tocopherol | 1件: D02332
D02332
(Name: Tocopherol) | - | - | 5件: 13 13, 49, 206, 257, 298 |
332 | Tocopherol (vit E) | 1件: Tocopherol Tocopherol | 1件: D02332
D02332
(Name: Tocopherol) | - | - | 1件: 257 257 |
333 | Tocopherol acetate | 3件: Acetate Acetate, Tocopherol, alpha-Tocopherol acetate | 1件: D02332
D02332
(Name: Tocopherol) | - | - | 1件: 49 49 |
334 | TOCOPHERYL ACETATE | 2件: Acetate Acetate, alpha-Tocopherol acetate | - | - | - | 1件: 206 206 |
335 | Tocotrienol | 1件: Tocotrienol Tocotrienol | - | - | - | 3件: 21 21, 156, 299 |
336 | Tocotrienols | - | - | - | - | 1件: 2 2 |
337 | Tocovid Suprabio (HOV-12020) | - | - | - | - | 1件: 6 6 |
338 | Toctino | 1件: Alitretinoin Alitretinoin (Synonym: Toctino) | 1件: D02815
D02815
| 5件: RARA RARA, RARB, RXRA, RXRB, RXRG 💬 | 19件: Acute myeloid leukemia Acute myeloid leukemia, Adipocytokine signaling pathway, Bile secretion, Chemical carcinogenesis - receptor activation, Estrogen signaling pathway, Gastric cancer, Hepatitis C, Lipid and atherosclerosis, Non-alcoholic fatty liver disease, Non-small cell lung cancer, PI3K-Akt signaling pathway, PPAR signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Small cell lung cancer, Th17 cell differentiation, Thyroid cancer, Thyroid hormone signaling pathway, Transcriptional misregulation in cancer 💬 | 1件: 49 49 |
339 | Toctino® | 1件: Alitretinoin Alitretinoin (Synonym: Toctino) | 1件: D02815
D02815
| 5件: RARA RARA, RARB, RXRA, RXRB, RXRG 💬 | 19件: Acute myeloid leukemia Acute myeloid leukemia, Adipocytokine signaling pathway, Bile secretion, Chemical carcinogenesis - receptor activation, Estrogen signaling pathway, Gastric cancer, Hepatitis C, Lipid and atherosclerosis, Non-alcoholic fatty liver disease, Non-small cell lung cancer, PI3K-Akt signaling pathway, PPAR signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Small cell lung cancer, Th17 cell differentiation, Thyroid cancer, Thyroid hormone signaling pathway, Transcriptional misregulation in cancer 💬 | 1件: 49 49 |
340 | TOFACINITIB | - | - | - | - | 1件: 97 97 |
341 | Tofacitinb | - | - | - | - | 1件: 46 46 |
342 | Tofacitinib | 1件: Tofacitinib Tofacitinib | 1件: D09970
D09970
(Name: Tofacitinib) | 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 15件: 11 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 |
343 | Tofacitinib (CP-690,550) | 1件: Tofacitinib Tofacitinib | 1件: D09970
D09970
(Name: Tofacitinib) | 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 96 96 |
344 | Tofacitinib (Xeljanz) | 1件: Tofacitinib Tofacitinib | 1件: D09970
D09970
(Name: Tofacitinib) | 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 46 46 |
345 | Tofacitinib (Xeljanz®) | 1件: Tofacitinib Tofacitinib | 1件: D09970
D09970
(Name: Tofacitinib) | 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 46 46 |
346 | Tofacitinib (Xeljanz®) 11mg Prolonged Release Tablet | 1件: Tofacitinib Tofacitinib | 1件: D09970
D09970
(Name: Tofacitinib) | 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 46 46 |
347 | Tofacitinib 10 mg | 1件: Tofacitinib Tofacitinib | 1件: D09970
D09970
(Name: Tofacitinib) | 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 271 271 |
348 | Tofacitinib 10 MG [Xeljanz] | 1件: Tofacitinib Tofacitinib | 1件: D09970
D09970
(Name: Tofacitinib) | 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 97 97 |
349 | Tofacitinib 2 mg | 1件: Tofacitinib Tofacitinib | 1件: D09970
D09970
(Name: Tofacitinib) | 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 271 271 |
350 | Tofacitinib 5 MG | 1件: Tofacitinib Tofacitinib | 1件: D09970
D09970
(Name: Tofacitinib) | 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 4件: 11 11, 40, 46, 271 |
351 | Tofacitinib 5 MG [Xeljanz] | 1件: Tofacitinib Tofacitinib | 1件: D09970
D09970
(Name: Tofacitinib) | 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 2件: 46 46, 50 |
352 | Tofacitinib 5 mg twice daily | 1件: Tofacitinib Tofacitinib | 1件: D09970
D09970
(Name: Tofacitinib) | 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 84 84 |
353 | Tofacitinib 5mg Oral Tablet [Xeljanz] 16 week trial | 1件: Tofacitinib Tofacitinib | 1件: D09970
D09970
(Name: Tofacitinib) | 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 84 84 |
354 | Tofacitinib 5mg po bid | 1件: Tofacitinib Tofacitinib | 1件: D09970
D09970
(Name: Tofacitinib) | 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 46 46 |
355 | Tofacitinib citate (Phase III formulation) | 1件: Tofacitinib Tofacitinib | 1件: D09970
D09970
(Name: Tofacitinib) | 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 46 46 |
356 | TOFACITINIB CITRATE | 1件: Tofacitinib Tofacitinib | 1件: D09970
D09970
(Name: Tofacitinib) | 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 5件: 46 46, 49, 97, 107, 271 |
357 | Tofacitinib citrate (clinical trial image) | 1件: Tofacitinib Tofacitinib | 1件: D09970
D09970
(Name: Tofacitinib) | 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 2件: 46 46, 97 |
358 | Tofacitinib citrate (commercial image) | 1件: Tofacitinib Tofacitinib | 1件: D09970
D09970
(Name: Tofacitinib) | 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 46 46 |
359 | Tofacitinib citrate (Phase III formulation) | 1件: Tofacitinib Tofacitinib | 1件: D09970
D09970
(Name: Tofacitinib) | 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 2件: 46 46, 97 |
360 | Tofacitinib citrate (Proposed commercial formulation - debossed) | 1件: Tofacitinib Tofacitinib | 1件: D09970
D09970
(Name: Tofacitinib) | 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 2件: 46 46, 97 |
361 | Tofacitinib citrate (Proposed commercial formulation debossed) | 1件: Tofacitinib Tofacitinib | 1件: D09970
D09970
(Name: Tofacitinib) | 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 46 46 |
362 | Tofacitinib citrate (Proposed commercial formulation – debossed) | 1件: Tofacitinib Tofacitinib | 1件: D09970
D09970
(Name: Tofacitinib) | 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 2件: 46 46, 97 |
363 | Tofacitinib citrate (Proposed commercial formulation- debossed) | 1件: Tofacitinib Tofacitinib | 1件: D09970
D09970
(Name: Tofacitinib) | 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 46 46 |
364 | Tofacitinib citrate (Proposed commercialFormulation - debossed) | 1件: Tofacitinib Tofacitinib | 1件: D09970
D09970
(Name: Tofacitinib) | 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 97 97 |
365 | TOFACITINIB CITRATE CP-690550 | 1件: Tofacitinib Tofacitinib | 1件: D09970
D09970
(Name: Tofacitinib) | 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 46 46 |
366 | Tofacitinib citrate( Phase III formulation) | 1件: Tofacitinib Tofacitinib | 1件: D09970
D09970
(Name: Tofacitinib) | 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 46 46 |
367 | Tofacitinib or Baricitinib | 2件: Baricitinib Baricitinib, Tofacitinib | 2件: D09970
D09970
(Name: Tofacitinib),
D10308
| 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 46 46 |
368 | Tofacitinib tablet | 1件: Tofacitinib Tofacitinib | 1件: D09970
D09970
(Name: Tofacitinib) | 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 40 40 |
369 | Tofacitinib with methotrexate | 2件: Methotrexate Methotrexate, Tofacitinib | 2件: D00142
D00142
,
D09970
(Name: Tofacitinib) | 6件: DHFR DHFR, DHFR2, JAK1, JAK2, JAK3, TYK2 💬 | 42件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Antifolate resistance, Biosynthesis of cofactors, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Folate biosynthesis, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, Metabolic pathways, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, One carbon pool by folate, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 46 46 |
370 | Tofacitinib without methotrexate | 2件: Methotrexate Methotrexate, Tofacitinib | 2件: D00142
D00142
,
D09970
(Name: Tofacitinib) | 6件: DHFR DHFR, DHFR2, JAK1, JAK2, JAK3, TYK2 💬 | 42件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Antifolate resistance, Biosynthesis of cofactors, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Folate biosynthesis, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, Metabolic pathways, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, One carbon pool by folate, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 46 46 |
371 | Tofacitinib XR | 1件: Tofacitinib Tofacitinib | 1件: D09970
D09970
(Name: Tofacitinib) | 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 2件: 46 46, 271 |
372 | Tofacitinib/baricitinib | 2件: Baricitinib Baricitinib, Tofacitinib | 2件: D09970
D09970
(Name: Tofacitinib),
D10308
| 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 46 46 |
373 | Tofacitinibe citrate | - | - | - | - | 1件: 107 107 |
374 | Tofersen | 1件: Tofersen Tofersen | 1件: D11811
D11811
(Name: Tofersen) | 1件: SOD1 SOD1 💬 | 8件: Amyotrophic lateral sclerosis Amyotrophic lateral sclerosis, Chemical carcinogenesis - reactive oxygen species, Huntington disease, Longevity regulating pathway - multiple species, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Peroxisome, Prion disease 💬 | 1件: 2 2 |
375 | TOL | - | - | - | - | 1件: 67 67 |
376 | Tolcapon | 1件: Tolcapone Tolcapone | 1件: D00786
D00786
(Name: Tolcapone) | 1件: COMT COMT 💬 | 4件: Dopaminergic synapse Dopaminergic synapse, Metabolic pathways, Steroid hormone biosynthesis, Tyrosine metabolism 💬 | 1件: 6 6 |
377 | TOLCAPONE | 1件: Tolcapone Tolcapone | 1件: D00786
D00786
(Name: Tolcapone) | 1件: COMT COMT 💬 | 4件: Dopaminergic synapse Dopaminergic synapse, Metabolic pathways, Steroid hormone biosynthesis, Tyrosine metabolism 💬 | 3件: 6 6, 28, 127 |
378 | TolDC | - | - | - | - | 1件: 46 46 |
379 | Tolebrutinib | - | - | - | - | 2件: 11 11, 13 |
380 | Tolebrutinib 120mg | - | - | - | - | 1件: 13 13 |
381 | Tolebrutinib 60mg | - | - | - | - | 1件: 13 13 |
382 | Tolebrutininb | - | - | - | - | 1件: 11 11 |
383 | Tolerogenic dendritic cells | - | - | - | - | 2件: 46 46, 96 |
384 | Tolerogenic dendritic cells (tolDC) | - | - | - | - | 1件: 13 13 |
385 | Tolerogenic Dendritic cells loaded with myelin peptides | 1件: Myelin basic protein Myelin basic protein | - | - | - | 1件: 13 13 |
386 | Tolerogenic Fibroblasts | - | - | - | - | 1件: 13 13 |
387 | Tolfenamic Acid | 1件: Tolfenamic acid Tolfenamic acid | 1件: D01183
D01183
(Name: Tolfenamic acid) | 2件: PTGS1 PTGS1, PTGS2 💬 | 23件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 5 5 |
388 | Tolicizumab | - | - | - | - | 1件: 46 46 |
389 | Tolicizumab Roche | - | - | - | - | 1件: 46 46 |
390 | Tolperisone | 1件: Tolperisone Tolperisone | 1件: D08617
D08617
(Name: Tolperisone) | - | - | 1件: 13 13 |
391 | Tolperisone HC1 | 1件: Tolperisone Tolperisone | 1件: D08617
D08617
(Name: Tolperisone) | - | - | 1件: 13 13 |
392 | Tolperisone HCl | 1件: Tolperisone Tolperisone | 1件: D08617
D08617
(Name: Tolperisone) | - | - | 1件: 13 13 |
393 | Tolpersan | - | - | - | - | 1件: 13 13 |
394 | Tolposan | - | - | - | - | 1件: 13 13 |
395 | Tolterodine | 1件: Tolterodine Tolterodine | 1件: D00646
D00646
(Name: Tolterodine) | 1件: CHRM3 CHRM3 💬 | 11件: Alzheimer disease Alzheimer disease, Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction 💬 | 2件: 17 17, 53 |
396 | Tolubuterol Hydrochloride | - | - | - | - | 1件: 6 6 |
397 | TOLVAPTAN | 1件: Tolvaptan Tolvaptan | 1件: D01213
D01213
(Name: Tolvaptan) | 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 4件: 67 67, 72, 86, 225 |
398 | TOLVAPTAN (OPC-41061) | 1件: Tolvaptan Tolvaptan | 1件: D01213
D01213
(Name: Tolvaptan) | 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 |
399 | Tolvaptan (SAMSCA) | 1件: Tolvaptan Tolvaptan | 1件: D01213
D01213
(Name: Tolvaptan) | 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 72 72 |
400 | TOLVAPTAN 15 | 1件: Tolvaptan Tolvaptan | 1件: D01213
D01213
(Name: Tolvaptan) | 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 |
401 | Tolvaptan 15 mg Tablet | 1件: Tolvaptan Tolvaptan | 1件: D01213
D01213
(Name: Tolvaptan) | 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 |
402 | Tolvaptan 15 mg tablets | 1件: Tolvaptan Tolvaptan | 1件: D01213
D01213
(Name: Tolvaptan) | 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 |
403 | Tolvaptan 15mg | 1件: Tolvaptan Tolvaptan | 1件: D01213
D01213
(Name: Tolvaptan) | 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 |
404 | TOLVAPTAN 30 | 1件: Tolvaptan Tolvaptan | 1件: D01213
D01213
(Name: Tolvaptan) | 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 |
405 | Tolvaptan 30 mg Tablet | 1件: Tolvaptan Tolvaptan | 1件: D01213
D01213
(Name: Tolvaptan) | 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 |
406 | Tolvaptan 30 mg tablets | 1件: Tolvaptan Tolvaptan | 1件: D01213
D01213
(Name: Tolvaptan) | 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 |
407 | Tolvaptan 30mg | 1件: Tolvaptan Tolvaptan | 1件: D01213
D01213
(Name: Tolvaptan) | 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 |
408 | TOLVAPTAN 45/15 | 1件: Tolvaptan Tolvaptan | 1件: D01213
D01213
(Name: Tolvaptan) | 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 |
409 | Tolvaptan 50mg Granules | 1件: Tolvaptan Tolvaptan | 1件: D01213
D01213
(Name: Tolvaptan) | 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 |
410 | TOLVAPTAN 60/30 | 1件: Tolvaptan Tolvaptan | 1件: D01213
D01213
(Name: Tolvaptan) | 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 |
411 | Tolvaptan 7.5 mg Tablet | 1件: Tolvaptan Tolvaptan | 1件: D01213
D01213
(Name: Tolvaptan) | 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 |
412 | Tolvaptan in euvolemic hyponatremia | 1件: Tolvaptan Tolvaptan | 1件: D01213
D01213
(Name: Tolvaptan) | 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 72 72 |
413 | Tolvaptan IR | 1件: Tolvaptan Tolvaptan | 1件: D01213
D01213
(Name: Tolvaptan) | 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 |
414 | Tolvaptan MR | 1件: Tolvaptan Tolvaptan | 1件: D01213
D01213
(Name: Tolvaptan) | 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 |
415 | Tolvaptan Oral Tablet | 1件: Tolvaptan Tolvaptan | 1件: D01213
D01213
(Name: Tolvaptan) | 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 72 72 |
416 | Tolvaptan Suspension | 1件: Tolvaptan Tolvaptan | 1件: D01213
D01213
(Name: Tolvaptan) | 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 |
417 | Tolvaptan Tablets | 1件: Tolvaptan Tolvaptan | 1件: D01213
D01213
(Name: Tolvaptan) | 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 |
418 | Tominersen | - | - | - | - | 1件: 8 8 |
419 | Tominersen 100 mg | - | - | - | - | 1件: 8 8 |
420 | Tominersen 60 mg | - | - | - | - | 1件: 8 8 |
421 | Top down treatment if patient at high risk | - | - | - | - | 2件: 96 96, 97 |
422 | Top-down | - | - | - | - | 1件: 96 96 |
423 | TOP1288 | - | - | - | - | 1件: 97 97 |
424 | TOP1288 Rectal solution | - | - | - | - | 1件: 97 97 |
425 | TOPAMAX | 1件: Topiramate Topiramate | 1件: D00537
D00537
(Name: Topiramate) | 36件: CA2 CA2, CA4, CACNA1C, CACNA1D, CACNA1F, CACNA1S, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GRIA1, GRIA2, GRIA3, GRIA4, GRIK1, GRIK2, GRIK3, GRIK4, GRIK5, SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 | 53件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Arrhythmogenic right ventricular cardiomyopathy, Bile secretion, Calcium signaling pathway, Carbohydrate digestion and absorption, Cardiac muscle contraction, Cellular senescence, Chemical carcinogenesis - receptor activation, Cholinergic synapse, Circadian entrainment, Cocaine addiction, Collecting duct acid secretion, Cortisol synthesis and secretion, Cushing syndrome, Dilated cardiomyopathy, Dopaminergic synapse, GABAergic synapse, Gastric acid secretion, Glutamatergic synapse, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Huntington disease, Hypertrophic cardiomyopathy, Insulin secretion, Long-term depression, Long-term potentiation, MAPK signaling pathway, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Nitrogen metabolism, Oxytocin signaling pathway, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Prion disease, Proximal tubule bicarbonate reclamation, Renin secretion, Retrograde endocannabinoid signaling, Serotonergic synapse, Spinocerebellar ataxia, Taste transduction, Tight junction, Transcriptional misregulation in cancer, Type II diabetes mellitus, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 140 140 |
426 | Topical 0.1% Sirolimus | 1件: Sirolimus Sirolimus | 1件: D00753
D00753
| 1件: MTOR MTOR 💬 | 51件: AMPK signaling pathway AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬 | 1件: 278 278 |
427 | Topical AmphiMatrix | - | - | - | - | 1件: 51 51 |
428 | Topical AmphiMatrix with nitroglycerin (MQX-503) | 1件: Nitroglycerin Nitroglycerin | 1件: D00515
D00515
| - | - | 1件: 51 51 |
429 | Topical beremagene geperpavec | - | - | - | - | 1件: 36 36 |
430 | Topical BPM31510 3.0% Cream | - | - | - | - | 1件: 36 36 |
431 | Topical calcipotriene 0.005% ointment | 1件: Calcipotriol Calcipotriol (Synonym: Dovonex Solution - Top 50mcg/ml) | 1件: D01125
D01125
| 1件: VDR VDR 💬 | 5件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬 | 1件: 51 51 |
432 | Topical compound tripterygium | 1件: Tripterygium wilfordii whole Tripterygium wilfordii whole | - | - | - | 1件: 46 46 |
433 | Topical garamycin cream | - | - | - | - | 2件: 35 35, 162 |
434 | Topical infliximab | 1件: Infliximab Infliximab | 1件: D02598
D02598
| 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 3件: 38 38, 39, 162 |
435 | Topical opiod | - | - | - | - | 1件: 36 36 |
436 | Topical organogel with nitroglycerin | 1件: Nitroglycerin Nitroglycerin | 1件: D00515
D00515
| - | - | 1件: 51 51 |
437 | Topical Pentoxifylline Gel (Vehicle +PTX) | 1件: Pentoxifylline Pentoxifylline | 1件: D00501
D00501
| - | - | 1件: 56 56 |
438 | Topical Preparation H arm | - | - | - | - | 1件: 13 13 |
439 | Topical Rapamycin | 1件: Sirolimus Sirolimus | 1件: D00753
D00753
| 1件: MTOR MTOR 💬 | 51件: AMPK signaling pathway AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬 | 1件: 157 157 |
440 | Topical timolol maleate | 1件: Timolol Timolol | 2件: D00378
D00378
,
D08600
| 2件: ADRB1 ADRB1, ADRB2 💬 | 11件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 227 227 |
441 | Topical tripterygium gel | 1件: Tripterygium wilfordii whole Tripterygium wilfordii whole | - | - | - | 1件: 46 46 |
442 | Topical Vehicle | - | - | - | - | 1件: 278 278 |
443 | Topimarate | - | - | - | - | 1件: 144 144 |
444 | Topimarato | - | - | - | - | 1件: 144 144 |
445 | TOPIRAMATE | 1件: Topiramate Topiramate | 1件: D00537
D00537
(Name: Topiramate) | 36件: CA2 CA2, CA4, CACNA1C, CACNA1D, CACNA1F, CACNA1S, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GRIA1, GRIA2, GRIA3, GRIA4, GRIK1, GRIK2, GRIK3, GRIK4, GRIK5, SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 | 53件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Arrhythmogenic right ventricular cardiomyopathy, Bile secretion, Calcium signaling pathway, Carbohydrate digestion and absorption, Cardiac muscle contraction, Cellular senescence, Chemical carcinogenesis - receptor activation, Cholinergic synapse, Circadian entrainment, Cocaine addiction, Collecting duct acid secretion, Cortisol synthesis and secretion, Cushing syndrome, Dilated cardiomyopathy, Dopaminergic synapse, GABAergic synapse, Gastric acid secretion, Glutamatergic synapse, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Huntington disease, Hypertrophic cardiomyopathy, Insulin secretion, Long-term depression, Long-term potentiation, MAPK signaling pathway, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Nitrogen metabolism, Oxytocin signaling pathway, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Prion disease, Proximal tubule bicarbonate reclamation, Renin secretion, Retrograde endocannabinoid signaling, Serotonergic synapse, Spinocerebellar ataxia, Taste transduction, Tight junction, Transcriptional misregulation in cancer, Type II diabetes mellitus, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 6件: 6 6, 97, 140, 144, 156, 193 |
446 | Topiramate (drug) | 1件: Topiramate Topiramate | 1件: D00537
D00537
(Name: Topiramate) | 36件: CA2 CA2, CA4, CACNA1C, CACNA1D, CACNA1F, CACNA1S, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GRIA1, GRIA2, GRIA3, GRIA4, GRIK1, GRIK2, GRIK3, GRIK4, GRIK5, SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 | 53件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Arrhythmogenic right ventricular cardiomyopathy, Bile secretion, Calcium signaling pathway, Carbohydrate digestion and absorption, Cardiac muscle contraction, Cellular senescence, Chemical carcinogenesis - receptor activation, Cholinergic synapse, Circadian entrainment, Cocaine addiction, Collecting duct acid secretion, Cortisol synthesis and secretion, Cushing syndrome, Dilated cardiomyopathy, Dopaminergic synapse, GABAergic synapse, Gastric acid secretion, Glutamatergic synapse, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Huntington disease, Hypertrophic cardiomyopathy, Insulin secretion, Long-term depression, Long-term potentiation, MAPK signaling pathway, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Nitrogen metabolism, Oxytocin signaling pathway, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Prion disease, Proximal tubule bicarbonate reclamation, Renin secretion, Retrograde endocannabinoid signaling, Serotonergic synapse, Spinocerebellar ataxia, Taste transduction, Tight junction, Transcriptional misregulation in cancer, Type II diabetes mellitus, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 6 6 |
447 | Topotecan | 1件: Topotecan Topotecan | 1件: D08618
D08618
(Name: Topotecan) | 1件: TOP1 TOP1 💬 | - | 1件: 25 25 |
448 | Torvast | - | - | - | - | 1件: 13 13 |
449 | TORVAST*10CPR 10MG | - | - | - | - | 1件: 13 13 |
450 | Total Body Irradiation | - | - | - | - | 1件: 65 65 |
451 | Total Body Irradiation (TBI) (Plan 1) | - | - | - | - | 2件: 60 60, 285 |
452 | Total Dietary Replacement | - | - | - | - | 1件: 265 265 |
453 | Total Glucosides Paeony Capsules | - | - | - | - | 1件: 271 271 |
454 | TOTTIZIM - 1 G/10 ML POLVERE E SOLVENTE PER SOLUZIONE INIETTABILE PER USO ENDOVENOSO 1 FLACONCINO POLVERE + 1 FIALA SOLVENTE 10 ML | - | - | - | - | 1件: 299 299 |
455 | Tovaxin | - | - | - | - | 1件: 13 13 |
456 | Tovaxin Autologous T Cell Vaccine | - | - | - | - | 1件: 13 13 |
457 | Toxicity, Pharmacokinetics | - | - | - | - | 1件: 34 34 |
458 | TOZ | - | - | - | - | 1件: 6 6 |
459 | TOZADENANT | 1件: Tozadenant Tozadenant | 1件: D10174
D10174
(Name: Tozadenant) | 1件: ADORA2A ADORA2A 💬 | 7件: Alcoholism Alcoholism, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway 💬 | 1件: 6 6 |
460 | Tozadenant (SYN115) 120 mg BID | 1件: Tozadenant Tozadenant | 1件: D10174
D10174
(Name: Tozadenant) | 1件: ADORA2A ADORA2A 💬 | 7件: Alcoholism Alcoholism, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway 💬 | 1件: 6 6 |
461 | Tozadenant (SYN115) 180 mg BID | 1件: Tozadenant Tozadenant | 1件: D10174
D10174
(Name: Tozadenant) | 1件: ADORA2A ADORA2A 💬 | 7件: Alcoholism Alcoholism, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway 💬 | 1件: 6 6 |
462 | Tozadenant (SYN115) 240 mg BID | 1件: Tozadenant Tozadenant | 1件: D10174
D10174
(Name: Tozadenant) | 1件: ADORA2A ADORA2A 💬 | 7件: Alcoholism Alcoholism, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway 💬 | 1件: 6 6 |
463 | Tozadenant (SYN115) 60 mg BID | 1件: Tozadenant Tozadenant | 1件: D10174
D10174
(Name: Tozadenant) | 1件: ADORA2A ADORA2A 💬 | 7件: Alcoholism Alcoholism, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway 💬 | 1件: 6 6 |
464 | Tozinameran | 1件: Tozinameran Tozinameran | 1件: D11971
D11971
(Name: Tozinameran) | - | - | 1件: 299 299 |
465 | Treat to target | - | - | - | - | 1件: 46 46 |
466 | Treatment with topical superpotent corticosteroid therapy | - | - | - | - | 1件: 162 162 |
467 | Untreated to atorvastatin treatment | 1件: Atorvastatin Atorvastatin | 1件: D07474
D07474
| 1件: HMGCR HMGCR 💬 | 4件: AMPK signaling pathway AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis 💬 | 1件: 13 13 |
468 | Urine samples taken to measure methotrexate and its major metabolite 7-OH-methotrexate level | 1件: Methotrexate Methotrexate | 1件: D00142
D00142
| 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 46 46 |
469 | Ursodeoxycholic acid combined with total glucosides of paeony | 1件: Ursodeoxycholic acid Ursodeoxycholic acid (Synonym: BAMBOO SALT Eunganggo Jook Yeom Toothpaste) | 1件: D00734
D00734
| 1件: NR1H4 NR1H4 💬 | 1件: Bile secretion Bile secretion 💬 | 1件: 93 93 |
470 | VACCINO HAEMOPHILUS INFLUENZAE B CONIUGATO CON TOSSOIDETETANICO | - | - | - | - | 2件: 61 61, 62 |
471 | Vantobra (tobramycin) | 1件: Tobramycin Tobramycin | 1件: D00063
D00063
(Name: Tobramycin) | - | - | 1件: 299 299 |
472 | Vedolizumab, Ustekinumab, or Tofacitinib | 3件: Tofacitinib Tofacitinib, Ustekinumab, Vedolizumab | 3件: D08083
D08083
,
D09214
,
D09970
(Name: Tofacitinib) | 9件: IL12A IL12A, IL12B, IL23A, ITGA4, ITGB7, JAK1, JAK2, JAK3, TYK2 💬 | 65件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Amoebiasis, Arrhythmogenic right ventricular cardiomyopathy, C-type lectin receptor signaling pathway, Cell adhesion molecules, Chagas disease, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, ECM-receptor interaction, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Focal adhesion, Growth hormone synthesis, secretion and action, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Legionellosis, Leishmaniasis, Leukocyte transendothelial migration, Lipid and atherosclerosis, Malaria, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pertussis, Primary immunodeficiency, Prolactin signaling pathway, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Regulation of actin cytoskeleton, Rheumatoid arthritis, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Transcriptional misregulation in cancer, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Yersinia infection 💬 | 1件: 97 97 |
473 | Vehicle of ADX-102 Topical Dermal Cream | - | - | - | - | 1件: 160 160 |
474 | Wound topically irrigated with 500mg TXA | - | - | - | - | 1件: 70 70 |
475 | XELJANZ (tofacitinib) | 1件: Tofacitinib Tofacitinib | 1件: D09970
D09970
(Name: Tofacitinib) | 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 65 65 |
476 | ZX008 0.2 to 0.8 mg/kg/day | - | - | - | - | 2件: 140 140, 144 |